Shared	O
gamma	B-protein
(	I-protein
c	I-protein
)	I-protein
subunit	I-protein
within	O
the	O
human	B-protein
interleukin-7	I-protein
receptor	I-protein
complex	I-protein
.	O

A	O
molecular	O
basis	O
for	O
the	O
pathogenesis	O
of	O
X-linked	O
severe	O
combined	O
immunodeficiency	O
.	O

Genetic	O
evidence	O
suggests	O
that	O
mutations	O
in	O
the	O
gamma	B-protein
(	I-protein
c	I-protein
)	I-protein
receptor	I-protein
subunit	I-protein
cause	O
X-linked	O
severe	O
combined	O
immunodeficiency	O
(	O
X-SCID	O
)	O
.	O

The	O
gamma	B-protein
(	I-protein
c	I-protein
)	I-protein
subunit	I-protein
can	O
be	O
employed	O
in	O
receptor	B-protein
complexes	I-protein
for	O
IL-2	B-protein
,	I-protein
-4	I-protein
,	I-protein
-7	I-protein
,	I-protein
-9	I-protein
,	I-protein
and	I-protein
-15	I-protein
,	O
and	O
the	O
multiple	O
signaling	O
defects	O
that	O
would	O
result	O
from	O
a	O
defective	O
gamma	B-protein
(	I-protein
c	I-protein
)	I-protein
chain	I-protein
in	O
these	O
receptors	O
are	O
proposed	O
to	O
cause	O
the	O
severe	O
phenotype	O
of	O
X-SCID	O
patients	O
.	O

Interestingly	O
,	O
gene	O
disruption	O
of	O
either	O
IL-7	B-protein
or	O
the	O
IL-7	B-protein
receptor	I-protein
(	I-protein
IL-7R	I-protein
)	I-protein
alpha	I-protein
subunit	I-protein
in	O
mice	O
leads	O
to	O
immunological	O
defects	O
that	O
are	O
similar	O
to	O
human	O
X-SCID	O
.	O

These	O
observations	O
suggest	O
the	O
functional	O
importance	O
of	O
gamma	B-protein
(	I-protein
c	I-protein
)	I-protein
in	O
the	O
IL-7R	B-protein
complex	I-protein
.	O

In	O
the	O
present	O
study	O
,	O
structure/function	O
analyses	O
of	O
the	O
IL-7R	B-protein
complex	I-protein
using	O
a	O
chimeric	B-protein
receptor	I-protein
system	O
demonstrated	O
that	O
gamma	B-protein
(	I-protein
c	I-protein
)	I-protein
is	O
indeed	O
critical	O
for	O
IL-7R	B-protein
function	O
.	O

Nonetheless	O
,	O
only	O
a	O
limited	O
portion	O
of	O
the	O
cytoplasmic	B-protein
domain	I-protein
of	O
gamma	B-protein
(	I-protein
c	I-protein
)	I-protein
is	O
necessary	O
for	O
IL-7R	B-protein
signal	O
transduction	O
.	O

Furthermore	O
,	O
replacement	O
of	O
the	O
gamma	B-protein
(	I-protein
c	I-protein
)	I-protein
cytoplasmic	B-protein
domain	I-protein
by	O
a	O
severely	B-protein
truncated	I-protein
erythropoeitin	I-protein
receptor	I-protein
does	O
not	O
affect	O
measured	O
IL-7R	B-protein
signaling	O
events	O
.	O

These	O
findings	O
support	O
a	O
model	O
in	O
which	O
gamma	B-protein
(	I-protein
c	I-protein
)	I-protein
serves	O
primarily	O
to	O
activate	O
signal	O
transduction	O
by	O
the	O
IL-7R	B-protein
complex	I-protein
,	O
while	O
IL-7R	B-protein
alpha	I-protein
determines	O
specific	O
signaling	O
events	O
through	O
its	O
association	O
with	O
cytoplasmic	B-protein
signaling	I-protein
molecules	I-protein
.	O

Finally	O
,	O
these	O
studies	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
the	O
molecular	O
pathogenesis	O
of	O
X-SCID	O
is	O
due	O
primarily	O
to	O
gamma	B-protein
(	I-protein
c	I-protein
)	I-protein
-mediated	O
defects	O
in	O
the	O
IL-7	B-protein
/IL-7R	B-protein
system	O

Rapid	NULL
Publication	NULL
Shared	NULL
y	NULL
,	NULL
,	NULL
Subunit	NULL
Within	NULL
the	NULL
Human	NULL
Interleukin-7	NULL
Receptor	NULL
Complex	NULL
A	NULL
Molecular	NULL
Basis	NULL
for	NULL
the	NULL
Pathogenesis	NULL
of	NULL
X-Linked	NULL
Severe	NULL
Combined	NULL
Immunodeficiency	NULL
Stephen	NULL
Y.	NULL
Lai	NULL
,	NULL
*	NULL
Jaime	NULL
Molden	NULL
,	NULL
*	NULL
and	NULL
Mark	NULL
A.	NULL
Goldsmith**	NULL
*Gladstone	NULL
Institute	NULL
of	NULL
Virology	NULL
and	NULL
Immunology	NULL
,	NULL
San	NULL
Francisco	NULL
,	NULL
California	NULL
94141-9100	NULL
;	NULL
and	NULL
*Department	NULL
of	NULL
Medicine	NULL
,	NULL
School	NULL
of	NULL
Medicine	NULL
,	NULL
University	NULL
of	NULL
California	NULL
,	NULL
San	NULL
Francisco	NULL
,	NULL
California	NULL
94122	NULL
Abstract	NULL
Genetic	NULL
evidence	NULL
suggests	NULL
that	NULL
mutations	NULL
in	NULL
the	NULL
y	NULL
,	NULL
receptor	NULL
subunit	NULL
cause	NULL
X-linked	NULL
severe	NULL
combined	NULL
immunodeficiency	NULL
(	NULL
X-SCID	NULL
)	NULL
.	NULL

The	NULL
y	NULL
,	NULL
subunit	NULL
can	NULL
be	NULL
employed	NULL
in	NULL
receptor	NULL
complexes	NULL
for	NULL
IL-2	NULL
,	NULL
-4	NULL
,	NULL
-7	NULL
,	NULL
-9	NULL
,	NULL
and	NULL
-15	NULL
,	NULL
and	NULL
the	NULL
multiple	NULL
signaling	NULL
defects	NULL
that	NULL
would	NULL
result	NULL
from	NULL
a	NULL
defective	NULL
y	NULL
,	NULL
chain	NULL
in	NULL
these	NULL
receptors	NULL
are	NULL
proposed	NULL
to	NULL
cause	NULL
the	NULL
severe	NULL
phenotype	NULL
of	NULL
X-SCID	NULL
patients	NULL
.	NULL

Interestingly	NULL
,	NULL
gene	NULL
disruption	NULL
of	NULL
either	NULL
IL-7	NULL
or	NULL
the	NULL
IL-7	NULL
receptor	NULL
(	NULL
IL-7R	NULL
)	NULL
«	NULL
subunit	NULL
in	NULL
mice	NULL
leads	NULL
to	NULL
immunological	NULL
defects	NULL
that	NULL
are	NULL
similar	NULL
to	NULL
human	NULL
X-SCID	NULL
.	NULL

These	NULL
observations	NULL
suggest	NULL
the	NULL
functional	NULL
importance	NULL
of	NULL
y	NULL
,	NULL
in	NULL
the	NULL
IL-7R	NULL
complex	NULL
.	NULL

In	NULL
the	NULL
present	NULL
study	NULL
,	NULL
structure/function	NULL
analyses	NULL
of	NULL
the	NULL
IL-7R	NULL
complex	NULL
using	NULL
a	NULL
chimeric	NULL
receptor	NULL
system	NULL
demonstrated	NULL
that	NULL
y	NULL
,	NULL
is	NULL
indeed	NULL
critical	NULL
for	NULL
IL-7R	NULL
function	NULL
.	NULL

Nonetheless	NULL
,	NULL
only	NULL
a	NULL
limited	NULL
portion	NULL
of	NULL
the	NULL
cytoplasmic	NULL
domain	NULL
of	NULL
y	NULL
,	NULL
is	NULL
necessary	NULL
for	NULL
IL-7R	NULL
signal	NULL
transduction	NULL
.	NULL

Furthermore	NULL
,	NULL
replacement	NULL
of	NULL
the	NULL
y	NULL
,	NULL
cytoplasmic	NULL
domain	NULL
by	NULL
a	NULL
severely	NULL
truncated	NULL
erythropoeitin	NULL
receptor	NULL
does	NULL
not	NULL
affect	NULL
measured	NULL
IL-7R	NULL
signaling	NULL
events	NULL
.	NULL

These	NULL
findings	NULL
support	NULL
a	NULL
model	NULL
in	NULL
which	NULL
y	NULL
,	NULL
serves	NULL
primarily	NULL
to	NULL
activate	NULL
signal	NULL
transduction	NULL
by	NULL
the	NULL
IL-7R	NULL
complex	NULL
,	NULL
while	NULL
IL-7Ra	NULL
determines	NULL
specific	NULL
signaling	NULL
events	NULL
through	NULL
its	NULL
association	NULL
with	NULL
cytoplasmic	NULL
signaling	NULL
molecules	NULL
.	NULL

Finally	NULL
,	NULL
these	NULL
studies	NULL
are	NULL
consistent	NULL
with	NULL
the	NULL
hypothesis	NULL
that	NULL
the	NULL
molecular	NULL
pathogenesis	NULL
of	NULL
X-SCID	NULL
is	NULL
due	NULL
primarily	NULL
to	NULL
y.-mediated	NULL
defects	NULL
in	NULL
the	NULL
IL-7/IL-7R	NULL
system	NULL
.	NULL

(	NULL
J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

1997	NULL
.	NULL

99:169-177	NULL
.	NULL
)	NULL

Key	NULL
words	NULL
:	NULL
interleukin-7	NULL
«	NULL
receptor	NULL
«	NULL
X-linked	NULL
severe	NULL
combined	NULL
immunodeficiency	NULL
«	NULL
signal	NULL
transduction	NULL
«	NULL
specificity	NULL
Introduction	NULL
Various	NULL
cytokines	NULL
contribute	NULL
to	NULL
the	NULL
development	NULL
and	NULL
regulation	NULL
of	NULL
lymphocytes	NULL
.	NULL

A	NULL
number	NULL
of	NULL
cytokines	NULL
including	NULL
IL-2	NULL
,	NULL
-4	NULL
,	NULL
-7	NULL
,	NULL
-9	NULL
,	NULL
and	NULL
-15	NULL
engage	NULL
receptor	NULL
complexes	NULL
composed	NULL
of	NULL
a	NULL
specific	NULL
subunit	NULL
in	NULL
conjunction	NULL
with	NULL
the	NULL
shared	NULL
y	NULL
,	NULL
chain	NULL
(	NULL
1-9	NULL
)	NULL
.	NULL

Hu-	NULL
Address	NULL
correspondence	NULL
to	NULL
Mark	NULL
A.	NULL
Goldsmith	NULL
,	NULL
Gladstone	NULL
Institute	NULL
of	NULL
Virology	NULL
and	NULL
Immunology	NULL
,	NULL
P.O	NULL
.	NULL

Box	NULL
419100	NULL
,	NULL
San	NULL
Francisco	NULL
,	NULL
CA	NULL
94141-9100	NULL
.	NULL

Phone	NULL
:	NULL
415-695-3775	NULL
;	NULL
FAX	NULL
:	NULL
415-826-1514	NULL
;	NULL
E-mail	NULL
:	NULL
mark	NULL
_	NULL
goldsmith.givi	NULL
@	NULL
quickmail.ucsf.edu	NULL
Received	NULL
for	NULL
publication	NULL
9	NULL
September	NULL
1996	NULL
and	NULL
accepted	NULL
in	NULL
revised	NULL
form	NULL
6	NULL
November	NULL
1996	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

©	NULL
The	NULL
American	NULL
Society	NULL
for	NULL
Clinical	NULL
Investigation	NULL
,	NULL
Inc.	NULL
0021-9738/97/01/169/09	NULL
$	NULL
2.00	NULL
Volume	NULL
99	NULL
,	NULL
Number	NULL
2	NULL
,	NULL
January	NULL
1997	NULL
,	NULL
169-177	NULL
man	NULL
mutations	NULL
in	NULL
y	NULL
,	NULL
have	NULL
been	NULL
linked	NULL
to	NULL
X-linked	NULL
severe	NULL
combined	NULL
immunodeficiency	NULL
(	NULL
X-SCID	NULL
)	NULL
,	NULL
!	NULL

a	NULL
disease	NULL
characterized	NULL
by	NULL
severe	NULL
lymphopenia	NULL
and	NULL
recurring	NULL
persistent	NULL
infections	NULL
in	NULL
the	NULL
first	NULL
months	NULL
of	NULL
life	NULL
(	NULL
10-12	NULL
)	NULL
.	NULL

Additionally	NULL
,	NULL
gene	NULL
deletion	NULL
studies	NULL
in	NULL
mice	NULL
of	NULL
y	NULL
,	NULL
have	NULL
revealed	NULL
a	NULL
similar	NULL
immunodeficiency	NULL
(	NULL
13	NULL
,	NULL
14	NULL
)	NULL
.	NULL

The	NULL
wide	NULL
array	NULL
of	NULL
receptor	NULL
signaling	NULL
defects	NULL
that	NULL
result	NULL
from	NULL
y	NULL
,	NULL
mutations	NULL
are	NULL
hypothesized	NULL
to	NULL
lead	NULL
to	NULL
the	NULL
severe	NULL
immunological	NULL
defects	NULL
found	NULL
in	NULL
both	NULL
X-SCID	NULL
patients	NULL
and	NULL
murine	NULL
models	NULL
.	NULL

Recent	NULL
studies	NULL
,	NULL
however	NULL
,	NULL
suggest	NULL
that	NULL
more	NULL
selective	NULL
signaling	NULL
defects	NULL
due	NULL
to	NULL
y	NULL
,	NULL
mutations	NULL
may	NULL
cause	NULL
X-SCID	NULL
and	NULL
the	NULL
murine	NULL
immunodeficiency	NULL
syndrome	NULL
.	NULL

Gene	NULL
ablation	NULL
of	NULL
IL-2	NULL
(	NULL
15	NULL
)	NULL
and	NULL
IL-2	NULL
receptor	NULL
(	NULL
IL-2R	NULL
)	NULL
B/IL-15RB	NULL
(	NULL
16	NULL
)	NULL
do	NULL
not	NULL
cause	NULL
early	NULL
developmental	NULL
defects	NULL
of	NULL
the	NULL
immune	NULL
system	NULL
.	NULL

Furthermore	NULL
,	NULL
IL-4	NULL
gene-ablation	NULL
studies	NULL
do	NULL
not	NULL
detect	NULL
early	NULL
lym-phopoietic	NULL
and	NULL
functional	NULL
disturbances	NULL
,	NULL
suggesting	NULL
that	NULL
y.-inde-pendent	NULL
forms	NULL
of	NULL
the	NULL
IL-4R	NULL
are	NULL
biologically	NULL
active	NULL
(	NULL
17-21	NULL
)	NULL
.	NULL

Additionally	NULL
,	NULL
the	NULL
role	NULL
of	NULL
y	NULL
,	NULL
in	NULL
the	NULL
IL-9R	NULL
complex	NULL
remains	NULL
undefined	NULL
.	NULL

The	NULL
y	NULL
,	NULL
subunit	NULL
does	NULL
not	NULL
appear	NULL
to	NULL
modulate	NULL
IL-9R	NULL
binding	NULL
affinity	NULL
for	NULL
IL-9	NULL
(	NULL
8	NULL
)	NULL
and	NULL
IL-9	NULL
may	NULL
act	NULL
primarily	NULL
on	NULL
mast	NULL
cells	NULL
(	NULL
22	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
gene	NULL
disruption	NULL
of	NULL
either	NULL
IL-7	NULL
(	NULL
23	NULL
)	NULL
or	NULL
the	NULL
IL-7Ra	NULL
subunit	NULL
(	NULL
24	NULL
)	NULL
leads	NULL
to	NULL
severe	NULL
developmental	NULL
perturba-tions	NULL
.	NULL

Thus	NULL
,	NULL
signaling	NULL
defects	NULL
in	NULL
the	NULL
IL-7/IL-7R	NULL
system	NULL
resulting	NULL
from	NULL
changes	NULL
in	NULL
y	NULL
,	NULL
may	NULL
be	NULL
sufficient	NULL
to	NULL
account	NULL
for	NULL
the	NULL
developmental	NULL
anomalies	NULL
that	NULL
lead	NULL
to	NULL
X-SCID	NULL
.	NULL

IL-7	NULL
was	NULL
identified	NULL
as	NULL
a	NULL
factor	NULL
secreted	NULL
by	NULL
stromal	NULL
cells	NULL
of	NULL
the	NULL
bone	NULL
marrow	NULL
and	NULL
thymus	NULL
that	NULL
stimulates	NULL
proliferation	NULL
of	NULL
immature	NULL
B	NULL
and	NULL
T	NULL
lymphocytes	NULL
(	NULL
25-31	NULL
)	NULL
.	NULL

The	NULL
biological	NULL
effects	NULL
of	NULL
IL-7	NULL
are	NULL
mediated	NULL
through	NULL
a	NULL
receptor	NULL
complex	NULL
containing	NULL
the	NULL
IL-7Ra	NULL
subunit	NULL
(	NULL
32	NULL
)	NULL
and	NULL
the	NULL
y	NULL
,	NULL
chain	NULL
(	NULL
3	NULL
,	NULL
6	NULL
,	NULL
9	NULL
)	NULL
.	NULL

Both	NULL
of	NULL
these	NULL
receptor	NULL
subunits	NULL
are	NULL
members	NULL
of	NULL
the	NULL
cytokine	NULL
receptor	NULL
superfamily	NULL
(	NULL
33	NULL
)	NULL
,	NULL
sharing	NULL
a	NULL
number	NULL
of	NULL
structural	NULL
features	NULL
including	NULL
two	NULL
partially	NULL
conserved	NULL
,	NULL
intracellular	NULL
regions	NULL
termed	NULL
Box1	NULL
and	NULL
Box2	NULL
that	NULL
are	NULL
involved	NULL
in	NULL
Janus	NULL
kinase	NULL
(	NULL
JAK	NULL
)	NULL
association	NULL
(	NULL
7	NULL
,	NULL
34-36	NULL
)	NULL
.	NULL

Engagement	NULL
of	NULL
these	NULL
subunits	NULL
by	NULL
IL-7	NULL
leads	NULL
to	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
Janus	NULL
kinases	NULL
,	NULL
JAK1	NULL
and	NULL
JAK3	NULL
,	NULL
and	NULL
the	NULL
subsequent	NULL
induction	NULL
of	NULL
a	NULL
signal	NULL
transducer	NULL
and	NULL
activator	NULL
of	NULL
transcription	NULL
(	NULL
STAT	NULL
)	NULL
factor	NULL
,	NULL
STAT-5	NULL
(	NULL
7	NULL
,	NULL
19	NULL
,	NULL
37	NULL
)	NULL
.	NULL

Additionally	NULL
,	NULL
activation	NULL
of	NULL
the	NULL
src-like	NULL
kinase	NULL
family	NULL
members	NULL
pS56lck	NULL
,	NULL
pS59fyn	NULL
,	NULL
and	NULL
p53/pS56lyn	NULL
has	NULL
been	NULL
reported	NULL
in	NULL
various	NULL
cellular	NULL
contexts	NULL
(	NULL
38-40	NULL
)	NULL
.	NULL

Downstream	NULL
of	NULL
the	NULL
activation	NULL
of	NULL
tyrosine	NULL
kinases	NULL
is	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
insulin	NULL
receptor	NULL
substrate-1	NULL
(	NULL
IRS-1	NULL
)	NULL
1	NULL
.	NULL

Abbreviations	NULL
used	NULL
in	NULL
this	NULL
paper	NULL
:	NULL
CMF-PBS	NULL
,	NULL
calcium-	NULL
and	NULL
magnesium-free	NULL
PBS	NULL
;	NULL
EMSA	NULL
,	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
;	NULL
EPOR	NULL
,	NULL
erythropoietin	NULL
receptor	NULL
;	NULL
IRS-1	NULL
,	NULL
insulin	NULL
receptor	NULL
substrate-1	NULL
;	NULL
JAK	NULL
,	NULL
Janus	NULL
kinase	NULL
;	NULL
STAT	NULL
,	NULL
signal	NULL
transducer	NULL
and	NULL
activator	NULL
of	NULL
transcription	NULL
;	NULL
X-SCID	NULL
,	NULL
X-linked	NULL
severe	NULL
combined	NULL
immunodeficiency	NULL
.	NULL

y	NULL
,	NULL
.	NULL

Mutations	NULL
Result	NULL
in	NULL
IL-7	NULL
Receptor	NULL
Signaling	NULL
Defects	NULL
169	NULL
(	NULL
41	NULL
)	NULL
and	NULL
phosphatidylinositol-3-kinase	NULL
(	NULL
42	NULL
,	NULL
43	NULL
)	NULL
.	NULL

Collectively	NULL
,	NULL
these	NULL
and	NULL
related	NULL
specific	NULL
molecular	NULL
events	NULL
culminate	NULL
in	NULL
differentiation	NULL
and	NULL
proliferation	NULL
by	NULL
IL-7	NULL
.	NULL

While	NULL
many	NULL
of	NULL
the	NULL
specific	NULL
signaling	NULL
events	NULL
activated	NULL
by	NULL
the	NULL
IL-7R	NULL
complex	NULL
have	NULL
been	NULL
delineated	NULL
,	NULL
the	NULL
functional	NULL
roles	NULL
of	NULL
the	NULL
receptor	NULL
subunits	NULL
themselves	NULL
in	NULL
generating	NULL
these	NULL
signals	NULL
are	NULL
relatively	NULL
undefined	NULL
.	NULL

However	NULL
,	NULL
the	NULL
heterodimeric	NULL
structure	NULL
of	NULL
the	NULL
IL-7R	NULL
complex	NULL
suggests	NULL
distinct	NULL
functions	NULL
for	NULL
the	NULL
individual	NULL
receptor	NULL
subunits	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
present	NULL
studies	NULL
were	NULL
undertaken	NULL
to	NULL
identify	NULL
the	NULL
functional	NULL
roles	NULL
of	NULL
IL-7Ra	NULL
«	NULL
and	NULL
y	NULL
,	NULL
within	NULL
the	NULL
IL-7R	NULL
complex	NULL
.	NULL

These	NULL
observations	NULL
define	NULL
the	NULL
structural	NULL
determinants	NULL
of	NULL
signaling	NULL
specificity	NULL
within	NULL
the	NULL
IL-7R	NULL
complex	NULL
and	NULL
further	NULL
clarify	NULL
mechanisms	NULL
associated	NULL
with	NULL
the	NULL
molecular	NULL
pathogenesis	NULL
of	NULL
X-SCID	NULL
.	NULL

Methods	NULL
Cell	NULL
lines	NULL
and	NULL
reagents	NULL
.	NULL

HT-2	NULL
,	NULL
an	NULL
IL-2-dependent	NULL
murine	NULL
helper	NULL
T	NULL
cell	NULL
line	NULL
(	NULL
American	NULL
Type	NULL
Culture	NULL
Collection	NULL
,	NULL
Rockville	NULL
,	NULL
MD	NULL
)	NULL
was	NULL
cultured	NULL
in	NULL
RPMI	NULL
1640	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
FBS	NULL
,	NULL
55	NULL
M	NULL
B-mercap-toethanol	NULL
(	NULL
B-ME	NULL
)	NULL
,	NULL
2	NULL
mM	NULL
L-glutamine	NULL
,	NULL
and	NULL
200	NULL
U/ml	NULL
recombinant	NULL
human	NULL
IL-2	NULL
(	NULL
a	NULL
generous	NULL
gift	NULL
of	NULL
Chiron	NULL
Corp	NULL
,	NULL
Emeryville	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

32D/	NULL
IRS-1	NULL
,	NULL
a	NULL
pro-myeloid	NULL
cell	NULL
line	NULL
stably	NULL
expressing	NULL
the	NULL
IRS-1	NULL
,	NULL
was	NULL
maintained	NULL
in	NULL
32D	NULL
medium	NULL
(	NULL
RPMI	NULL
1640	NULL
containing	NULL
10	NULL
%	NULL
FBS	NULL
and	NULL
5	NULL
%	NULL
WEHI	NULL
3B-conditioned	NULL
medium	NULL
)	NULL
.	NULL

The	NULL
SCID-MA	NULL
cell	NULL
line	NULL
was	NULL
maintained	NULL
in	NULL
RPMI	NULL
1640	NULL
with	NULL
10	NULL
%	NULL
FBS	NULL
,	NULL
10	NULL
mM	NULL
Hepes	NULL
,	NULL
2	NULL
mM	NULL
L-glutamine	NULL
,	NULL
and	NULL
5	NULL
M	NULL
B-ME	NULL
.	NULL

Electroporation	NULL
of	NULL
cells	NULL
was	NULL
performed	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
44	NULL
)	NULL
,	NULL
and	NULL
stable	NULL
transfectants	NULL
were	NULL
obtained	NULL
by	NULL
selection	NULL
in	NULL
G418	NULL
(	NULL
1	NULL
mg/ml	NULL
Geneticin	NULL
;	NULL
GIBCO	NULL
BRL	NULL
,	NULL
Life	NULL
Technologies	NULL
,	NULL
Inc.	NULL
,	NULL
Gaithers-burg	NULL
,	NULL
MD	NULL
)	NULL
.	NULL

Clones	NULL
isolated	NULL
by	NULL
limiting	NULL
dilution	NULL
were	NULL
screened	NULL
by	NULL
Northern	NULL
blot	NULL
analysis	NULL
to	NULL
identify	NULL
clones	NULL
expressing	NULL
the	NULL
transfected	NULL
receptor	NULL
subunit	NULL
(	NULL
s	NULL
)	NULL
.	NULL

HT-2	NULL
stable	NULL
cell	NULL
lines	NULL
expressing	NULL
two	NULL
receptor	NULL
subunits	NULL
were	NULL
derived	NULL
from	NULL
cells	NULL
already	NULL
expressing	NULL
either	NULL
the	NULL
EPOy	NULL
or	NULL
EPOyYF	NULL
chain	NULL
.	NULL

After	NULL
electroporation	NULL
,	NULL
stable	NULL
transfectants	NULL
were	NULL
isolated	NULL
by	NULL
selection	NULL
in	NULL
G418	NULL
(	NULL
1	NULL
mg/m	NULL
!	NULL
)	NULL

and	NULL
hygromycin	NULL
B	NULL
(	NULL
500	NULL
pg/	NULL
ml	NULL
;	NULL
Boehringer	NULL
Mannheim	NULL
Biochemicals	NULL
,	NULL
Indianapolis	NULL
,	NULL
IN	NULL
)	NULL
and	NULL
screened	NULL
by	NULL
Northern	NULL
blot	NULL
analysis	NULL
.	NULL

The	NULL
antiphosphotyrosine	NULL
monoclonal	NULL
antibody	NULL
(	NULL
4G10	NULL
)	NULL
,	NULL
anti-JAK1	NULL
,	NULL
-JAK2	NULL
,	NULL
and	NULL
-JAK3	NULL
were	NULL
obtained	NULL
from	NULL
Upstate	NULL
Biotechnology	NULL
Inc.	NULL
(	NULL
Lake	NULL
Placid	NULL
,	NULL
NY	NULL
)	NULL
.	NULL

Human	NULL
IL-4	NULL
and	NULL
IL-9	NULL
were	NULL
obtained	NULL
from	NULL
R	NULL
&	NULL
D	NULL
Systems	NULL
,	NULL
Inc.	NULL
(	NULL
Minneapolis	NULL
,	NULL
MN	NULL
)	NULL
.	NULL

Recombinant	NULL
human	NULL
IL-7	NULL
was	NULL
from	NULL
Genzyme	NULL
,	NULL
Corp.	NULL
(	NULL
Cam-bridge	NULL
,	NULL
MA	NULL
)	NULL
and	NULL
recombinant	NULL
human	NULL
EPO	NULL
was	NULL
the	NULL
generous	NULL
gift	NULL
of	NULL
Ortho	NULL
Diagnostic	NULL
Systems	NULL
Inc.	NULL
(	NULL
Raritan	NULL
,	NULL
NJ	NULL
)	NULL
.	NULL

Plasmid	NULL
constructs	NULL
.	NULL

All	NULL
receptor	NULL
cDNAs	NULL
were	NULL
subcloned	NULL
into	NULL
the	NULL
expression	NULL
vectors	NULL
pCMV4Neo	NULL
(	NULL
44	NULL
)	NULL
or	NULL
pCMV4Hygro	NULL
,	NULL
a	NULL
derivative	NULL
of	NULL
pCMV4	NULL
(	NULL
45	NULL
)	NULL
containing	NULL
a	NULL
hygromycin	NULL
B-resistance	NULL
gene	NULL
as	NULL
a	NULL
select-able	NULL
marker	NULL
.	NULL

The	NULL
cytoplasmic	NULL
portion	NULL
of	NULL
the	NULL
IL-7Ra	NULL
subunit	NULL
was	NULL
isolated	NULL
by	NULL
PCR	NULL
from	NULL
PBMC	NULL
cDNA	NULL
.	NULL

pEPOT7neo	NULL
was	NULL
constructed	NULL
by	NULL
PCR	NULL
using	NULL
a	NULL
Nhel	NULL
site	NULL
at	NULL
the	NULL
fusion	NULL
junction	NULL
.	NULL

The	NULL
chimeric	NULL
receptor	NULL
subunit	NULL
contains	NULL
the	NULL
extracellular	NULL
domain	NULL
of	NULL
the	NULL
erythopoietin	NULL
receptor	NULL
(	NULL
EPOR	NULL
)	NULL
fused	NULL
just	NULL
above	NULL
the	NULL
transmembrane	NULL
segment	NULL
to	NULL
the	NULL
human	NULL
IL-7Ra	NULL
transmembrane	NULL
and	NULL
cytoplasmic	NULL
domains	NULL
(	NULL
resulting	NULL
se-quence	NULL
:	NULL
.	NULL

.	NULL

.	NULL

(	NULL
EPOR-T-A-S	NULL
)	NULL
-	NULL
(	NULL
I-N-N-IL-7a	NULL
)	NULL
.	NULL

.	NULL

.	NULL
)	NULL

.	NULL

The	NULL
EPOy	NULL
and	NULL
the	NULL
chimeric	NULL
y	NULL
,	NULL
receptor	NULL
mutants	NULL
were	NULL
constructed	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
46	NULL
)	NULL
.	NULL

A	NULL
stop	NULL
codon	NULL
was	NULL
introduced	NULL
at	NULL
the	NULL
HindIII	NULL
site	NULL
present	NULL
in	NULL
the	NULL
coding	NULL
sequence	NULL
of	NULL
EPO7	NULL
to	NULL
create	NULL
the	NULL
subunit	NULL
that	NULL
lacks	NULL
the	NULL
distal	NULL
100	NULL
amino	NULL
acid	NULL
residues	NULL
.	NULL

For	NULL
all	NULL
constructs	NULL
requiring	NULL
synthetic	NULL
oligonucleotides	NULL
or	NULL
PCR	NULL
reactions	NULL
,	NULL
sequences	NULL
were	NULL
confirmed	NULL
by	NULL
DNA	NULL
sequencing	NULL
.	NULL

JAK	NULL
and	NULL
IRS-1	NULL
phosphorylation	NULL
studies	NULL
.	NULL

40	NULL
X	NULL
10°	NULL
cells	NULL
were	NULL
washed	NULL
twice	NULL
in	NULL
calcium-	NULL
and	NULL
magnesium-free	NULL
phosphate-buffered	NULL
saline	NULL
(	NULL
CMF-PBS	NULL
)	NULL
,	NULL
stripped	NULL
of	NULL
cell-bound	NULL
ligand	NULL
for	NULL
1	NULL
min	NULL
in	NULL
10	NULL
mM	NULL
sodium	NULL
citrate	NULL
,	NULL
pH	NULL
4.0	NULL
,	NULL
and	NULL
140	NULL
mM	NULL
NaCl	NULL
and	NULL
rested	NULL
for	NULL
4	NULL
h	NULL
or	NULL
overnight	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
containing	NULL
1	NULL
%	NULL
bovine	NULL
serum	NULL
albumin	NULL
(	NULL
fraction	NULL
V	NULL
;	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
,	NULL
St.	NULL
Louis	NULL
,	NULL
MO	NULL
)	NULL
.	NULL

After	NULL
stimulation	NULL
with	NULL
the	NULL
170	NULL
_	NULL
Lai	NULL
et	NULL
al	NULL
.	NULL

appropriate	NULL
factor	NULL
,	NULL
cells	NULL
were	NULL
washed	NULL
in	NULL
CMF-PBS	NULL
and	NULL
lysed	NULL
(	NULL
1	NULL
%	NULL
Nonidet	NULL
P-40	NULL
,	NULL
20	NULL
mM	NULL
Tris-HCI	NULL
,	NULL
pH	NULL
8.0	NULL
,	NULL
and	NULL
150	NULL
mM	NULL
NaCl	NULL
,	NULL
50	NULL
mM	NULL
NaF	NULL
,	NULL
100	NULL
mM	NULL
sodium	NULL
orthovanadate	NULL
,	NULL
1	NULL
mM	NULL
phenylmethylsulfonyl	NULL
fluoride	NULL
,	NULL
10	NULL
pg/ml	NULL
leupeptin	NULL
,	NULL
10	NULL
pg/ml	NULL
aprotinin	NULL
,	NULL
1	NULL
pg/ml	NULL
pepstatin	NULL
A.	NULL
Immunoprecipitations	NULL
were	NULL
performed	NULL
with	NULL
the	NULL
indicated	NULL
antibodies	NULL
and	NULL
protein	NULL
A-Sepharose	NULL
.	NULL

Immunoblot	NULL
analysis	NULL
was	NULL
performed	NULL
with	NULL
the	NULL
appropriate	NULL
antibodies	NULL
with	NULL
detection	NULL
by	NULL
ECL	NULL
(	NULL
Amersham	NULL
Corp.	NULL
,	NULL
Arlington	NULL
Heights	NULL
,	NULL
IL	NULL
)	NULL
signal	NULL
development	NULL
.	NULL

For	NULL
JAK	NULL
analysis	NULL
,	NULL
blots	NULL
were	NULL
stripped	NULL
(	NULL
100	NULL
mM	NULL
2-mercaptoethanol	NULL
,	NULL
2	NULL
%	NULL
sodium	NULL
dodecyl	NULL
sul-phate	NULL
,	NULL
62.5	NULL
mM	NULL
Tris-HCl	NULL
,	NULL
pH	NULL
6.7	NULL
)	NULL
for	NULL
30	NULL
min	NULL
at	NULL
55°C	NULL
and	NULL
reprobed	NULL
with	NULL
anti-JAK1	NULL
and	NULL
-JAK3	NULL
antisera	NULL
to	NULL
verify	NULL
equivalent	NULL
protein	NULL
loading	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
.	NULL

40-60	NULL
x	NULL
10°	NULL
cells	NULL
were	NULL
rested	NULL
and	NULL
stimulated	NULL
as	NULL
described	NULL
above	NULL
and	NULL
washed	NULL
in	NULL
CMF-PBS	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
as	NULL
described	NULL
(	NULL
47	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
1	NULL
mM	NULL
sodium	NULL
orthovanadate	NULL
and	NULL
the	NULL
following	NULL
protease	NULL
inhibitors	NULL
(	NULL
in	NULL
g/ml	NULL
)	NULL
:	NULL
antipain	NULL
0.5	NULL
,	NULL
aprotinin	NULL
0.5	NULL
,	NULL
bestatin	NULL
0.75	NULL
,	NULL
leupeptin	NULL
0.5	NULL
,	NULL
pepstatin	NULL
A	NULL
0.05	NULL
,	NULL
phosphoramidon	NULL
1.4	NULL
,	NULL
and	NULL
soybean	NULL
trypsin	NULL
inhibitor	NULL
0.5	NULL
(	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
)	NULL
.	NULL

The	NULL
IgG	NULL
Fc	NULL
receptor	NULL
STAT	NULL
response	NULL
element	NULL
probe	NULL
was	NULL
end-labeled	NULL
with	NULL
[	NULL
y-*P	NULL
]	NULL
dATP	NULL
(	NULL
Amersham	NULL
Corp.	NULL
)	NULL
and	NULL
polynucle-otide	NULL
kinase	NULL
(	NULL
New	NULL
England	NULL
Biolabs	NULL
Inc.	NULL
,	NULL
Beverly	NULL
,	NULL
MA	NULL
)	NULL
.	NULL

DNA	NULL
binding	NULL
studies	NULL
were	NULL
performed	NULL
with	NULL
10°	NULL
cpm	NULL
probe	NULL
,	NULL
3	NULL
ug	NULL
poly	NULL
[	NULL
d	NULL
(	NULL
I-C	NULL
)	NULL
]	NULL
and	NULL
10	NULL
g	NULL
nuclear	NULL
extract	NULL
as	NULL
described	NULL
(	NULL
47a	NULL
)	NULL
.	NULL

Preincubation	NULL
of	NULL
nuclear	NULL
extracts	NULL
with	NULL
different	NULL
antibodies	NULL
were	NULL
performed	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
SCID-MA	NULL
U	NULL
4	NULL
2	NULL
7	NULL
9	NULL
#	NULL
but	NULL
1s	NULL
Figure	NULL
1	NULL
.	NULL

The	NULL
y	NULL
,	NULL
mutation	NULL
in	NULL
an	NULL
X-SCID	NULL
patient	NULL
results	NULL
in	NULL
multiple	NULL
cytokine	NULL
receptor	NULL
signaling	NULL
defects	NULL
.	NULL

40	NULL
x	NULL
10°	NULL
cells/sample	NULL
were	NULL
unstimulated	NULL
(	NULL
U	NULL
)	NULL
or	NULL
stimulated	NULL
for	NULL
15	NULL
minutes	NULL
with	NULL
various	NULL
cytokines	NULL
:	NULL
IL-4	NULL
(	NULL
4	NULL
,	NULL
100	NULL
ng/ml	NULL
)	NULL
,	NULL
IL-2	NULL
(	NULL
2	NULL
,	NULL
10	NULL
nM	NULL
)	NULL
,	NULL
IL-7	NULL
(	NULL
7	NULL
,	NULL
100	NULL
U/ml	NULL
)	NULL
,	NULL
and	NULL
IL-9	NULL
(	NULL
9	NULL
,	NULL
100	NULL
U/ml	NULL
)	NULL
.	NULL

EMSA	NULL
of	NULL
prepared	NULL
nuclear	NULL
exracts	NULL
are	NULL
shown	NULL
.	NULL

Cytokine	NULL
bioactivity	NULL
was	NULL
verified	NULL
by	NULL
stimulation	NULL
of	NULL
various	NULL
responsive	NULL
cell	NULL
lines	NULL
and	NULL
the	NULL
integrity	NULL
of	NULL
the	NULL
nuclear	NULL
extracts	NULL
was	NULL
verified	NULL
by	NULL
EMSA	NULL
with	NULL
the	NULL
SP-1	NULL
probe	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Arrow	NULL
denotes	NULL
IL-4-induced	NULL
STAT-6	NULL
DNA-binding	NULL
activity	NULL
.	NULL

Probe	NULL
poly	NULL
[	NULL
d	NULL
(	NULL
I-C	NULL
)	NULL
]	NULL
and	NULL
binding	NULL
buffer	NULL
for	NULL
45	NULL
min	NULL
on	NULL
ice	NULL
before	NULL
initiation	NULL
of	NULL
the	NULL
binding	NULL
assay	NULL
by	NULL
addition	NULL
of	NULL
radiolabeled	NULL
probe	NULL
.	NULL

Proliferation	NULL
assays	NULL
.	NULL

Conventional	NULL
24-h	NULL
[	NULL
H	NULL
]	NULL
thymidine	NULL
(	NULL
DuPont-NEN	NULL
,	NULL
Boston	NULL
,	NULL
MA	NULL
)	NULL
incorporation	NULL
assays	NULL
were	NULL
performed	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
44	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
32D	NULL
cells	NULL
were	NULL
counted	NULL
,	NULL
washed	NULL
twice	NULL
in	NULL
CMF-PBS	NULL
and	NULL
resuspended	NULL
at	NULL
10°	NULL
cells/ml	NULL
of	NULL
32D	NULL
medium	NULL
without	NULL
the	NULL
WEHI	NULL
3B-conditioned	NULL
medium	NULL
supplement	NULL
.	NULL

10°	NULL
cells	NULL
per	NULL
well	NULL
were	NULL
grown	NULL
in	NULL
the	NULL
indicated	NULL
concentrations	NULL
of	NULL
EPO	NULL
for	NULL
24	NULL
h	NULL
with	NULL
[	NULL
H	NULL
]	NULL
thymidine	NULL
incorporation	NULL
measured	NULL
in	NULL
the	NULL
last	NULL
4	NULL
h.	NULL
Transient	NULL
transfection	NULL
assays	NULL
of	NULL
EPO-induced	NULL
proliferation	NULL
were	NULL
performed	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
44	NULL
)	NULL
.	NULL

incorporation	NULL
was	NULL
measured	NULL
on	NULL
days	NULL
8-16	NULL
after	NULL
transfection	NULL
.	NULL

B	NULL
IP	NULL
:	NULL
JAK1	NULL
|	NULL
|	NULL
A	NULL
HT-2EPOT7	NULL
HT-2EPOY	NULL
HT-2EPO7/Y	NULL
IL-7R	NULL
EPOT7	NULL
U	NULL
E	NULL
2	NULL
U	NULL
E	NULL
2	NULL
U	NULL
E	NULL
2	NULL
&	NULL
Yo	NULL
EPOR	NULL
-	NULL
EPO7	NULL
EPOY	NULL
|	NULL
EPOY	NULL
ug	NULL
_	NULL
114	NULL
-	NULL
y	NULL
IP	NULL
:	NULL
JAK3	NULL
-	NULL
]	NULL
T	NULL
‘	NULL
5	NULL
HT-2EPOT7	NULL
HT-2EPOY	NULL
HT-2EPOT7/	NULL
}	NULL
Y	NULL
U	NULL
E	NULL
2	NULL
U	NULL
E	NULL
2	NULL
U	NULL
E	NULL
2	NULL
140	NULL
-	NULL
___	NULL
h	NULL
B	NULL
llis	NULL
-	NULL
'	NULL
f	NULL
oor	NULL
``	NULL
--	NULL
114	NULL
-	NULL
f	NULL
C	NULL
D	NULL
HT-2	NULL
HT-2	NULL
EPO7	NULL
EPOY	NULL
-	NULL
EPOT7Y	NULL
U	NULL
E	NULL
2	NULL
U	NULL
E	NULL
2	NULL
U	NULL
E	NULL
2	NULL
E	NULL
E	NULL
EPO7/Y	NULL
EPOT7/	NULL
}	NULL
YYF	NULL
EPO7/YYF	NULL
U	NULL
E	NULL
2	NULL
U	NULL
E	NULL
2	NULL
U	NULL
E	NULL
2	NULL
lll	NULL
wes	NULL
mo	NULL
.	NULL

_	NULL
*M	NULL
”	NULL
Hf	NULL
,	NULL
I	NULL
“	NULL
*	NULL
Figure	NULL
2	NULL
.	NULL

A	NULL
chimeric	NULL
receptor	NULL
system	NULL
recapitulates	NULL
IL-7	NULL
receptor-mediated	NULL
signaling	NULL
events	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Schematic	NULL
representation	NULL
of	NULL
native	NULL
(	NULL
IL-7Ra	NULL
,	NULL
y	NULL
,	NULL
,	NULL
and	NULL
EPOR	NULL
)	NULL
and	NULL
chimeric	NULL
(	NULL
EPO7	NULL
and	NULL
EPOy	NULL
)	NULL
subunits	NULL
Tan	NULL
A	NULL
fused	NULL
at	NULL
a	NULL
site	NULL
located	NULL
immediately	NULL
NH	NULL
,	NULL
-terminal	NULL
to	NULL
the	NULL
transmem-K9	NULL
)	NULL
,	NULL
K9	NULL
)	NULL
;	NULL
brane	NULL
segment	NULL
.	NULL

The	NULL
partially	NULL
conserved	NULL
Box1	NULL
and	NULL
Box2	NULL
domains	NULL
of	NULL
q	NULL
pA	NULL
4	NULL
»	NULL
the	NULL
cytoplasmic	NULL
portion	NULL
of	NULL
members	NULL
of	NULL
the	NULL
cytokine	NULL
receptor	NULL
super-*	NULL
is	NULL
family	NULL
are	NULL
shown	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Lysates	NULL
of	NULL
unstimulated	NULL
(	NULL
U	NULL
)	NULL
,	NULL
EPO-stimulated	NULL
4	NULL
G	NULL
(	NULL
E	NULL
,	NULL
50	NULL
U/m1	NULL
)	NULL
,	NULL
and	NULL
IL-2-stimulated	NULL
(	NULL
2	NULL
,	NULL
10	NULL
nM	NULL
)	NULL
cells	NULL
were	NULL
subjected	NULL
to	NULL
immunoprecipitations	NULL
for	NULL
JAK1	NULL
and	NULL
JAK3	NULL
.	NULL

Immunoblot	NULL
analysis	NULL
was	NULL
performed	NULL
with	NULL
the	NULL
antiphosphotyrosine	NULL
antibody	NULL
.	NULL

Verification	NULL
of	NULL
E	NULL
protein	NULL
loading	NULL
was	NULL
demonstrated	NULL
by	NULL
stripping	NULL
the	NULL
blot	NULL
and	NULL
perform	NULL
ing	NULL
immunoblot	NULL
with	NULL
anti-JAK1	NULL
and	NULL
-JAK3	NULL
antibodies	NULL
(	NULL
data	NULL
not	NULL
IP	NULL
:	NULL
STAT-5A	NULL
STAT-5B	NULL
STAT-5A	NULL
STAT-5B	NULL
shown	NULL
)	NULL
.	NULL

Arrows	NULL
denote	NULL
JAK1	NULL
and	NULL
JAK3	NULL
.	NULL

(	NULL
C	NULL
)	NULL
EMSA	NULL
of	NULL
nuclear	NULL
L	NULL
,	NULL
i	NULL
’	NULL
i	NULL
‘	NULL
A	NULL
44	NULL
U	NULL
OE	NULL
U	NULL
E	NULL
U	NULL
E	NULL
U	NULL
E	NULL
extracts	NULL
from	NULL
unstimulated	NULL
(	NULL
U	NULL
)	NULL
,	NULL
EPO-stimulated	NULL
(	NULL
£	NULL
)	NULL
,	NULL
and	NULL
IL-2-stimulated	NULL
(	NULL
2	NULL
)	NULL
cell	NULL
lines	NULL
.	NULL

Competition	NULL
was	NULL
performed	NULL
with	NULL
the	NULL
anti-STAT-5A	NULL
and	NULL
-5B	NULL
antibodies	NULL
.	NULL

Arrow	NULL
indicates	NULL
STAT-5	NULL
DNA-binding	NULL
activ-	NULL
h	NULL
th	NULL
>	NULL
il	NULL
Jyoti	NULL
,	NULL
6	NULL
;	NULL
ity	NULL
.	NULL

N.S	NULL
.	NULL

,	NULL
nonspecific	NULL
band	NULL
.	NULL

(	NULL
D	NULL
)	NULL
EMSA	NULL
of	NULL
nuclear	NULL
extracts	NULL
from	NULL
the	NULL
}	NULL
indicated	NULL
cell	NULL
lines	NULL
.	NULL

Arrow	NULL
indicates	NULL
STAT-5	NULL
DNA	NULL
binding	NULL
activity	NULL
.	NULL

P	NULL
4	NULL
(	NULL
E	NULL
)	NULL
anti-STAT-5A	NULL
and	NULL
-5B	NULL
immunoprecipitates	NULL
of	NULL
unstimulated	NULL
(	NULL
U	NULL
)	NULL
and	NULL
EPO-stimulated	NULL
(	NULL
£	NULL
)	NULL
32D/IRS-1/EPO77	NULL
cells	NULL
were	NULL
analyzed	NULL
by	NULL
W	NULL
:	NULL
STAT-5A	NULL
PTyr	NULL
SDS-PAGE	NULL
and	NULL
immunoblotted	NULL
with	NULL
the	NULL
indicated	NULL
antibodies	NULL
.	NULL

y	NULL
,	NULL
.	NULL

Mutations	NULL
Result	NULL
in	NULL
IL-7	NULL
Receptor	NULL
Signaling	NULL
Defects	NULL
171	NULL
Results	NULL
B	NULL
cells	NULL
from	NULL
an	NULL
X-SCID	NULL
patient	NULL
are	NULL
unresponsive	NULL
to	NULL
multiple	NULL
cytokines	NULL
that	NULL
bind	NULL
to	NULL
receptor	NULL
complexes	NULL
containing	NULL
the	NULL
y	NULL
,	NULL
subunit	NULL
.	NULL

Epstein-Barr	NULL
virus-transformed	NULL
B	NULL
cell	NULL
lines	NULL
derived	NULL
from	NULL
X-SCID	NULL
patients	NULL
have	NULL
various	NULL
mutations	NULL
in	NULL
the	NULL
y	NULL
,	NULL
gene	NULL
.	NULL

For	NULL
example	NULL
,	NULL
the	NULL
SCID-MA	NULL
cell	NULL
line	NULL
contains	NULL
a	NULL
mutation	NULL
that	NULL
results	NULL
in	NULL
the	NULL
lack	NULL
of	NULL
detectable	NULL
mRNA	NULL
transcripts	NULL
for	NULL
the	NULL
y	NULL
,	NULL
subunit	NULL
(	NULL
reference	NULL
12	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

To	NULL
assess	NULL
the	NULL
functional	NULL
consequences	NULL
of	NULL
this	NULL
genetic	NULL
defect	NULL
,	NULL
SCID-MA	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
cytokines	NULL
that	NULL
employ	NULL
y	NULL
,	NULL
-containing	NULL
receptor	NULL
complexes	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

The	NULL
activation	NULL
of	NULL
STAT	NULL
factors	NULL
was	NULL
evaluated	NULL
in	NULL
an	NULL
electrophoretic	NULL
mobility	NULL
gel	NULL
shift	NULL
assay	NULL
(	NULL
EMSA	NULL
)	NULL
using	NULL
an	NULL
oligonucleotide	NULL
probe	NULL
that	NULL
contains	NULL
the	NULL
IgG	NULL
Fc	NULL
receptor	NULL
promoter	NULL
element	NULL
.	NULL

SCID-MA	NULL
cells	NULL
retained	NULL
responsiveness	NULL
to	NULL
IL-4	NULL
,	NULL
as	NULL
demonstrated	NULL
by	NULL
the	NULL
retarded	NULL
mobility	NULL
of	NULL
the	NULL
radiolabeled	NULL
probe	NULL
and	NULL
anti-STAT-6	NULL
antibody	NULL
competition	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Previous	NULL
studies	NULL
are	NULL
consistent	NULL
with	NULL
the	NULL
hypothesis	NULL
that	NULL
IL-4	NULL
may	NULL
engage	NULL
another	NULL
receptor	NULL
com-plex	NULL
(	NULL
es	NULL
)	NULL
that	NULL
does	NULL
not	NULL
require	NULL
the	NULL
y	NULL
,	NULL
subunit	NULL
(	NULL
17-21	NULL
)	NULL
.	NULL

However	NULL
,	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
a	NULL
functional	NULL
y	NULL
,	NULL
chain	NULL
,	NULL
SCID-MA	NULL
cells	NULL
were	NULL
unresponsive	NULL
to	NULL
IL-2	NULL
,	NULL
-7	NULL
,	NULL
and	NULL
-9	NULL
,	NULL
raising	NULL
the	NULL
possibility	NULL
that	NULL
y	NULL
,	NULL
is	NULL
critical	NULL
for	NULL
signaling	NULL
by	NULL
these	NULL
receptor	NULL
systems	NULL
.	NULL

Since	NULL
IL-2	NULL
and	NULL
IL-9	NULL
do	NULL
not	NULL
appear	NULL
to	NULL
affect	NULL
early	NULL
lymphocyte	NULL
devel-opment	NULL
,	NULL
further	NULL
analysis	NULL
of	NULL
the	NULL
IL-7R	NULL
complex	NULL
and	NULL
its	NULL
link	NULL
to	NULL
X-SCID	NULL
was	NULL
undertaken	NULL
.	NULL

A	NULL
chimeric	NULL
receptor	NULL
system	NULL
recapitulates	NULL
JAK-STAT	NULL
signaling	NULL
of	NULL
the	NULL
IL-7	NULL
receptor	NULL
complex	NULL
.	NULL

To	NULL
investigate	NULL
the	NULL
functional	NULL
roles	NULL
of	NULL
the	NULL
individual	NULL
receptor	NULL
subunits	NULL
in	NULL
the	NULL
IL-7	NULL
receptor	NULL
complex	NULL
,	NULL
chimeric	NULL
receptor	NULL
subunits	NULL
were	NULL
formed	NULL
by	NULL
fusing	NULL
the	NULL
extracellular	NULL
domain	NULL
of	NULL
the	NULL
EPOR	NULL
to	NULL
the	NULL
intracellular	NULL
portions	NULL
of	NULL
IL-7Ra	NULL
and	NULL
y	NULL
,	NULL
to	NULL
form	NULL
EPOT7	NULL
and	NULL
EPOy	NULL
,	NULL
respectively	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
A	NULL
)	NULL
.	NULL

These	NULL
chimeric	NULL
receptor	NULL
subunits	NULL
were	NULL
evaluated	NULL
for	NULL
their	NULL
abilities	NULL
to	NULL
recapitulate	NULL
IL-7	NULL
receptor	NULL
signaling	NULL
,	NULL
specifically	NULL
through	NULL
the	NULL
JAK-STAT	NULL
pathway	NULL
.	NULL

Stable	NULL
transfectants	NULL
expressing	NULL
EPOT7	NULL
or	NULL
EPOy	NULL
were	NULL
established	NULL
in	NULL
HT-2	NULL
cells	NULL
,	NULL
a	NULL
murine	NULL
helper	NULL
T	NULL
cell	NULL
line	NULL
.	NULL

Antiphosphotyrosine	NULL
immunoblot	NULL
analysis	NULL
of	NULL
JAK	NULL
kinase	NULL
immunoprecipitates	NULL
from	NULL
HT-2	NULL
stable	NULL
transfectants	NULL
demonstrated	NULL
the	NULL
phosphorylation	NULL
of	NULL
JAK1	NULL
and	NULL
JAK3	NULL
,	NULL
but	NULL
not	NULL
JAK2	NULL
,	NULL
in	NULL
response	NULL
to	NULL
a	NULL
positive	NULL
control	NULL
ligand	NULL
,	NULL
IL-2	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
B	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Upon	NULL
EPO	NULL
stimulation	NULL
,	NULL
neither	NULL
the	NULL
HT-2EPO7	NULL
nor	NULL
the	NULL
HT-2EPOy	NULL
cell	NULL
lines	NULL
demonstrated	NULL
an	NULL
increase	NULL
in	NULL
the	NULL
phosphorylation	NULL
of	NULL
JAK1	NULL
and	NULL
JAK3	NULL
when	NULL
compared	NULL
with	NULL
unstimulated	NULL
cells	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
a	NULL
stable	NULL
cell	NULL
line	NULL
expressing	NULL
both	NULL
EPO7	NULL
and	NULL
EPOy	NULL
subunits	NULL
,	NULL
HT-2EPOT7y	NULL
,	NULL
displayed	NULL
a	NULL
marked	NULL
increase	NULL
in	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
JAK1	NULL
and	NULL
JAK3	NULL
in	NULL
response	NULL
to	NULL
EPO	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
B	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
activation	NULL
of	NULL
the	NULL
chimeric	NULL
receptor	NULL
system	NULL
leads	NULL
to	NULL
the	NULL
induction	NULL
of	NULL
the	NULL
same	NULL
JAK	NULL
kinases	NULL
as	NULL
those	NULL
reportedly	NULL
linked	NULL
to	NULL
the	NULL
native	NULL
IL-7	NULL
receptor	NULL
complex	NULL
(	NULL
7	NULL
,	NULL
37	NULL
,	NULL
48	NULL
)	NULL
.	NULL

Activation	NULL
of	NULL
JAK	NULL
kinases	NULL
in	NULL
cytokine	NULL
receptor	NULL
complexes	NULL
typically	NULL
leads	NULL
to	NULL
the	NULL
recruitment	NULL
and	NULL
activation	NULL
of	NULL
STAT	NULL
fac-	NULL
é	NULL
EPO7	NULL
EPOR	NULL
(	NULL
1-321	NULL
)	NULL
EPOT/EPOR	NULL
(	NULL
1-321	NULL
)	NULL
P	NULL
3g	NULL
100	NULL
100	NULL
100	NULL
IP	NULL
:	NULL
-	NULL
JAK1	NULL
JAK2	NULL
JAK3	NULL
éﬁ	NULL
so	NULL
so	NULL
so	NULL
32D/IRS-1	NULL
-	NULL
U	NULL
E	NULL
U	NULL
E	NULL
U	NULL
E	NULL
83	NULL
so	NULL
so	NULL
eo	NULL
*-Te-=-o=-*-=	NULL
£22	NULL
40	NULL
40	NULL
40	NULL
EPOT	NULL
'	NULL
Y	NULL
«	NULL
uas	NULL
-f	NULL
Eé	NULL
20	NULL
20	NULL
20	NULL
E	NULL
``	NULL
oo	NULL
ioto0o	NULL
-	NULL
``	NULL
oo	NULL
dioiioioiso	NULL
-	NULL
oo	NULL
moiioioico	NULL
-	NULL
EPOT7/EPOR	NULL
vag	NULL
€	NULL
(	NULL
1-321	NULL
)	NULL
ld	NULL
EPO	NULL
(	NULL
U/ml	NULL
)	NULL
D	NULL
32D/IRS-1	NULL
c	NULL
EPOT7/EPOR	NULL
32D/IRS-1	NULL
_EPO7Y	NULL
_	NULL
(	NULL
1321	NULL
)	NULL
U	NULL
E	NULL
U	NULL
E	NULL
EPOT7/EPOR	NULL
-	NULL
EPOR	NULL
vates	NULL
EPO7	NULL
EPO	NULL
'	NULL
Y	NULL
EPOTY	NULL
(	NULL
1-321	NULL
)	NULL
(	NULL
1-321	NULL
)	NULL
w	NULL
U	NULL
E	NULL
W	NULL
U	NULL
E	NULL
W	NULL
U	NULL
E	NULL
W	NULL
U	NULL
E	NULL
W	NULL
|	NULL
MMW	NULL
,	NULL
Mb	NULL
.	NULL

.\	NULL
iM	NULL
J	NULL
Figure	NULL
3	NULL
.	NULL

The	NULL
functional	NULL
replacement	NULL
of	NULL
y	NULL
,	NULL
by	NULL
a	NULL
truncated	NULL
EPOR	NULL
does	NULL
not	NULL
alter	NULL
specific	NULL
signaling	NULL
events	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Stable	NULL
32D/IRS-1	NULL
transfectants	NULL
were	NULL
stimulated	NULL
with	NULL
EPO	NULL
in	NULL
[	NULL
H	NULL
]	NULL
thymidine	NULL
incorporation	NULL
experiments	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Serial	NULL
immunoprecipitates	NULL
of	NULL
JAK1	NULL
,	NULL
JAK2	NULL
,	NULL
and	NULL
JAK3	NULL
from	NULL
lysates	NULL
of	NULL
the	NULL
indicated	NULL
cell	NULL
lines	NULL
.	NULL

Immunoblot	NULL
analysis	NULL
was	NULL
performed	NULL
with	NULL
the	NULL
antiphosphotyrosine	NULL
antibody	NULL
.	NULL

Verification	NULL
of	NULL
protein	NULL
loading	NULL
was	NULL
demonstrated	NULL
by	NULL
stripping	NULL
the	NULL
blot	NULL
and	NULL
performing	NULL
immunoblot	NULL
analysis	NULL
with	NULL
the	NULL
anti-JAK1	NULL
,	NULL
-JAK2	NULL
and	NULL
-JAK3	NULL
antibodies	NULL
.	NULL

Arrowheads	NULL
denote	NULL
JAK1	NULL
(	NULL
solid	NULL
)	NULL
,	NULL
JAK2	NULL
(	NULL
hatched	NULL
)	NULL
,	NULL
and	NULL
JAK3	NULL
(	NULL
open	NULL
)	NULL
.	NULL

(	NULL
C	NULL
)	NULL
EMSA	NULL
of	NULL
nuclear	NULL
extracts	NULL
from	NULL
the	NULL
indicated	NULL
32D/IRS-1	NULL
stable	NULL
transfectants	NULL
that	NULL
were	NULL
unstimulated	NULL
(	NULL
U	NULL
)	NULL
or	NULL
treated	NULL
with	NULL
EPO	NULL
(	NULL
F	NULL
)	NULL
or	NULL
Wehi	NULL
3B-conditioned	NULL
media	NULL
(	NULL
W	NULL
,	NULL
10	NULL
%	NULL
)	NULL
.	NULL

Arrow	NULL
depicts	NULL
STAT-5	NULL
DNA-binding	NULL
activity	NULL
.	NULL

(	NULL
D	NULL
)	NULL
anti-IRS-1	NULL
immunoprecipitates	NULL
of	NULL
lysates	NULL
from	NULL
the	NULL
indicated	NULL
cell	NULL
lines	NULL
that	NULL
were	NULL
unstimulated	NULL
(	NULL
U	NULL
)	NULL
or	NULL
EPO	NULL
stimulated	NULL
(	NULL
£	NULL
)	NULL
.	NULL

Immunoblotting	NULL
was	NULL
performed	NULL
with	NULL
the	NULL
antiphosphotyrosine	NULL
antibody	NULL
.	NULL

172	NULL
-	NULL
Lai	NULL
etal	NULL
.	NULL

tors	NULL
(	NULL
49	NULL
)	NULL
.	NULL

As	NULL
demonstrated	NULL
by	NULL
EMSA	NULL
using	NULL
a	NULL
probe	NULL
corresponding	NULL
to	NULL
the	NULL
IgG	NULL
Fc	NULL
receptor	NULL
STAT	NULL
responsive	NULL
element	NULL
,	NULL
EPO	NULL
stimulation	NULL
of	NULL
HT-2EPOT7	NULL
and	NULL
HT-2EPOy	NULL
cell	NULL
lines	NULL
did	NULL
not	NULL
result	NULL
in	NULL
activation	NULL
of	NULL
a	NULL
specific	NULL
DNA-binding	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
C	NULL
)	NULL
.	NULL

Like	NULL
the	NULL
native	NULL
IL-7	NULL
receptor	NULL
complex	NULL
(	NULL
19	NULL
)	NULL
,	NULL
engagement	NULL
of	NULL
both	NULL
chimeric	NULL
receptor	NULL
subunits	NULL
by	NULL
EPO	NULL
stimulation	NULL
of	NULL
the	NULL
HT-2EPOT7y	NULL
cell	NULL
line	NULL
resulted	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
STAT-5	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
C	NULL
)	NULL
.	NULL

This	NULL
DNA-binding	NULL
complex	NULL
contained	NULL
both	NULL
STAT-5A	NULL
and	NULL
-5B	NULL
,	NULL
as	NULL
demonstrated	NULL
by	NULL
specific	NULL
antibody	NULL
competition	NULL
that	NULL
diminished	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
retarded	NULL
nu-cleoprotein	NULL
complex	NULL
.	NULL

To	NULL
examine	NULL
the	NULL
IL-7R	NULL
complex	NULL
in	NULL
another	NULL
cell	NULL
context	NULL
,	NULL
the	NULL
chimeric	NULL
receptor	NULL
system	NULL
was	NULL
also	NULL
established	NULL
in	NULL
32D/IRS-1	NULL
,	NULL
a	NULL
promyeloid	NULL
cell	NULL
line	NULL
that	NULL
expresses	NULL
IRS-1	NULL
(	NULL
50	NULL
)	NULL
.	NULL

As	NULL
in	NULL
the	NULL
HT-2	NULL
cell	NULL
line	NULL
,	NULL
EPO	NULL
stimulation	NULL
of	NULL
32D/IRS-1	NULL
stable	NULL
transfectants	NULL
expressing	NULL
EPO7	NULL
or	NULL
EPOy	NULL
alone	NULL
did	NULL
not	NULL
affect	NULL
the	NULL
phosphorylation	NULL
of	NULL
JAK1	NULL
or	NULL
JAK3	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

EPO	NULL
stimulation	NULL
of	NULL
a	NULL
32D/IRS-1	NULL
stable	NULL
cell	NULL
line	NULL
expressing	NULL
both	NULL
EPO7	NULL
and	NULL
EPOy	NULL
(	NULL
32D/IRS-1/EPO7y	NULL
)	NULL
resulted	NULL
in	NULL
a	NULL
marked	NULL
increase	NULL
in	NULL
the	NULL
phosphorylation	NULL
of	NULL
JAK1	NULL
and	NULL
JAK3	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
B	NULL
)	NULL
.	NULL

Additionally	NULL
,	NULL
EPO	NULL
stimulation	NULL
of	NULL
32D/IRS-1/EPOT7	NULL
and	NULL
32D/IRS-1/EPOy	NULL
cell	NULL
lines	NULL
did	NULL
not	NULL
result	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
DNA-binding	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
C	NULL
)	NULL
.	NULL

However	NULL
,	NULL
EPO	NULL
stimulation	NULL
of	NULL
a	NULL
32D	NULL
cell	NULL
line	NULL
expressing	NULL
both	NULL
EPO7	NULL
and	NULL
EPOy	NULL
,	NULL
32D/IRS-1/EPOT7y	NULL
,	NULL
led	NULL
to	NULL
the	NULL
activation	NULL
of	NULL
a	NULL
DNA-binding	NULL
complex	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
C	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
the	NULL
composition	NULL
of	NULL
the	NULL
DNA-binding	NULL
complex	NULL
,	NULL
32D/IRS-1/	NULL
EPO7	NULL
cellular	NULL
lysates	NULL
were	NULL
subjected	NULL
to	NULL
immunoprecipitation	NULL
with	NULL
the	NULL
STAT-5A	NULL
and	NULL
-5B	NULL
antibodies	NULL
after	NULL
activation	NULL
of	NULL
the	NULL
EPO7/EPOy	NULL
heterodimer	NULL
.	NULL

Anti-STAT-5A	NULL
immunoblot	NULL
analysis	NULL
of	NULL
the	NULL
immunoprecipitates	NULL
demonstrated	NULL
the	NULL
coimmuno-precipitation	NULL
of	NULL
STAT-5B	NULL
with	NULL
STAT-5A	NULL
after	NULL
EPO	NULL
stimulation	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
£	NULL
)	NULL
.	NULL

Similarly	NULL
,	NULL
immunoprecipitates	NULL
of	NULL
the	NULL
STAT-5A	NULL
antibody	NULL
demonstrated	NULL
the	NULL
EPO-induced	NULL
association	NULL
of	NULL
STAT-5B	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
as	NULL
in	NULL
the	NULL
IL-2R	NULL
system	NULL
(	NULL
51	NULL
)	NULL
,	NULL
signaling	NULL
through	NULL
the	NULL
IL-7Ra/y	NULL
,	NULL
heterodimer	NULL
results	NULL
in	NULL
the	NULL
activation	NULL
and	NULL
heterodimerization	NULL
of	NULL
STAT-5A	NULL
and	NULL
-5B	NULL
.	NULL

Thus	NULL
,	NULL
these	NULL
findings	NULL
demonstrate	NULL
that	NULL
signaling	NULL
by	NULL
the	NULL
IL-7	NULL
receptor	NULL
complex	NULL
through	NULL
the	NULL
JAK-STAT	NULL
pathway	NULL
is	NULL
reproduced	NULL
by	NULL
the	NULL
chimeric	NULL
receptor	NULL
system	NULL
in	NULL
two	NULL
cytokine-dependent	NULL
hematopoietic	NULL
cell	NULL
lines	NULL
.	NULL

Furthermore	NULL
,	NULL
heterodimerization	NULL
of	NULL
the	NULL
cytoplasmic	NULL
tails	NULL
of	NULL
IL-7Ra	NULL
and	NULL
y	NULL
,	NULL
are	NULL
required	NULL
to	NULL
activate	NULL
signal	NULL
transduction	NULL
by	NULL
the	NULL
IL-7R	NULL
complex	NULL
.	NULL

The	NULL
cytoplasmic	NULL
tyrosines	NULL
of	NULL
the	NULL
y	NULL
,	NULL
subunit	NULL
are	NULL
not	NULL
required	NULL
for	NULL
JAK-STAT	NULL
signaling	NULL
by	NULL
the	NULL
IL-7R	NULL
complex	NULL
.	NULL

Previous	NULL
studies	NULL
in	NULL
the	NULL
IL-2	NULL
and	NULL
IL-4	NULL
receptor	NULL
complexes	NULL
demonstrated	NULL
that	NULL
the	NULL
four	NULL
cytoplasmic	NULL
tyrosine	NULL
residues	NULL
of	NULL
the	NULL
y	NULL
,	NULL
subunit	NULL
were	NULL
dispensable	NULL
for	NULL
signal	NULL
transduction	NULL
in	NULL
response	NULL
to	NULL
those	NULL
cytokines	NULL
(	NULL
20	NULL
,	NULL
46	NULL
,	NULL
51	NULL
)	NULL
.	NULL

To	NULL
investigate	NULL
the	NULL
functional	NULL
role	NULL
of	NULL
the	NULL
tyrosine	NULL
residues	NULL
of	NULL
the	NULL
y	NULL
,	NULL
subunit	NULL
in	NULL
the	NULL
IL-7R	NULL
complex	NULL
,	NULL
HT-2	NULL
stable	NULL
cell	NULL
lines	NULL
were	NULL
established	NULL
that	NULL
expressed	NULL
EPO7	NULL
and	NULL
EPOyYF	NULL
,	NULL
a	NULL
chimeric	NULL
y	NULL
,	NULL
.	NULL

mutant	NULL
in	NULL
which	NULL
all	NULL
four	NULL
cytoplasmic	NULL
tyrosine	NULL
residues	NULL
are	NULL
replaced	NULL
by	NULL
phenylalanines	NULL
.	NULL

Like	NULL
wild-type	NULL
HT-2EPO7y	NULL
cells	NULL
,	NULL
EPO-stimulation	NULL
of	NULL
two	NULL
distinct	NULL
HT-2EPO7/yYF	NULL
cell	NULL
lines	NULL
resulted	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
a	NULL
DNA-binding	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
D	NULL
)	NULL
.	NULL

Additionally	NULL
,	NULL
antibody	NULL
competition	NULL
experiments	NULL
confirmed	NULL
the	NULL
presence	NULL
of	NULL
STAT-5A	NULL
and	NULL
-5B	NULL
in	NULL
B	NULL
C	NULL
€	NULL
&	NULL
150000	NULL
``	NULL
fut	NULL
c	NULL
-*-	NULL
vector	NULL
e	NULL
§	NULL
-=-	NULL
EPOy	NULL
-	NULL
ower	NULL
S	NULL
EPOT	NULL
EPOy	NULL
EPOT/EPOy	NULL
5	NULL
100000	NULL
§	NULL
100	NULL
3	NULL
800m	NULL
$	NULL
yese	NULL
$	NULL
#	NULL
£	NULL
Ea	NULL
so	NULL
$	NULL
5	NULL
w	NULL
é	NULL
50000	NULL
yo18	NULL
28	NULL
B	NULL
5°	NULL
_	NULL
»	NULL
&	NULL
,	NULL
E0	NULL
-=	NULL
oms	NULL
E	NULL
0	NULL
ym	NULL
``	NULL
i	NULL
0.0	NULL
.01	NULL
0.1	NULL
1.0	NULL
10	NULL
100	NULL
0.0.01	NULL
0.1	NULL
1.0	NULL
10	NULL
100	NULL
0.0	NULL
.01	NULL
0.1	NULL
1.0	NULL
10	NULL
100	NULL
E	NULL
6	NULL
8	NULL
10	NULL
12	NULL
14	NULL
EPO	NULL
&	NULL
DAY	NULL
E	NULL
32D/IRS-1/EPOT	NULL
D	NULL
32D/IRS-1/EPOT	NULL
T	NULL
E	NULL
100000	NULL
&	NULL
100000	NULL
yAaBox2	NULL
&	NULL
-*-	NULL
EPOWF	NULL
-	NULL
§	NULL
-L-	NULL
_	NULL
EPOyAV-Box	NULL
B	NULL
-=-	NULL
Epoypse	NULL
&	NULL
-*-	NULL
EPOyABox1	NULL
8	NULL
-*-	NULL
EPOg18	NULL
-	NULL
$	NULL
-*-	NULL
EPOyABox2	NULL
3	NULL
-*-	NULL
EPOyTM	NULL
_	NULL
§	NULL
8	NULL
50000	NULL
\	NULL
§	NULL
50000	NULL
g	NULL
€	NULL
p	NULL
£	NULL
3	NULL
3	NULL
E	NULL
/	NULL
E	NULL
2	NULL
2	NULL
E	NULL
o	NULL
E.	NULL
0	NULL
-	NULL
2	NULL
T	NULL
-	NULL
'	NULL
£	NULL
,	NULL
60080	NULL
0	NULL
400	NULL
120	NULL
14	NULL
E	NULL
6	NULL
8	NULL
10	NULL
12	NULL
14	NULL
DAY	NULL
DAY	NULL
Figure	NULL
4	NULL
.	NULL

Heterodimerization	NULL
of	NULL
the	NULL
IL-7Ra	NULL
and	NULL
y	NULL
,	NULL
cytoplasmic	NULL
domains	NULL
results	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
IL-7-specific	NULL
signaling	NULL
events	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Stable	NULL
32D/IRS-1	NULL
transfectants	NULL
were	NULL
stimulated	NULL
with	NULL
EPO	NULL
in	NULL
incorporation	NULL
experiments	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Transient	NULL
transfection	NULL
assay	NULL
of	NULL
32D/IRS-1/	NULL
EPOT7	NULL
cells	NULL
demonstrates	NULL
that	NULL
EPO-induced	NULL
proliferation	NULL
requires	NULL
the	NULL
presence	NULL
of	NULL
both	NULL
EPOT7	NULL
and	NULL
EPOy	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Schematic	NULL
diagram	NULL
of	NULL
the	NULL
y	NULL
,	NULL
mu-tants	NULL
.	NULL

y336	NULL
,	NULL
y318	NULL
and	NULL
yTM	NULL
mutants	NULL
are	NULL
truncated	NULL
immediately	NULL
after	NULL
amino	NULL
acids	NULL
336	NULL
,	NULL
318	NULL
,	NULL
and	NULL
286	NULL
,	NULL
respectively	NULL
.	NULL

yABox1	NULL
lacks	NULL
residues	NULL
281-294	NULL
,	NULL
yAV-BOX	NULL
lacks	NULL
residues	NULL
295-320	NULL
,	NULL
and	NULL
yABox2	NULL
lacks	NULL
residues	NULL
321-334	NULL
.	NULL

(	NULL
D	NULL
)	NULL
Transfection	NULL
assay	NULL
of	NULL
32D/IRS-1/EPOT7	NULL
cells	NULL
with	NULL
various	NULL
EPOy	NULL
mutants	NULL
demonstrates	NULL
the	NULL
critical	NULL
role	NULL
of	NULL
the	NULL
cytoplasmic	NULL
membrane	NULL
proximal	NULL
region	NULL
of	NULL
y	NULL
,	NULL
for	NULL
growth	NULL
signaling	NULL
.	NULL

(	NULL
E	NULL
)	NULL
Evaluation	NULL
of	NULL
internal	NULL
deletion	NULL
mutants	NULL
of	NULL
y	NULL
,	NULL
by	NULL
the	NULL
transient	NULL
transfection	NULL
assay	NULL
.	NULL

Each	NULL
transfection	NULL
assay	NULL
done	NULL
in	NULL
32D/IRS-1/EPO7	NULL
cells	NULL
included	NULL
EPOy	NULL
as	NULL
a	NULL
positive	NULL
control	NULL
.	NULL

y	NULL
,	NULL
.	NULL

Mutations	NULL
Result	NULL
in	NULL
IL-7	NULL
Receptor	NULL
Signaling	NULL
Defects	NULL
173	NULL
this	NULL
DNA-binding	NULL
complex	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
as	NULL
in	NULL
other	NULL
~y-containing	NULL
receptor	NULL
complexes	NULL
,	NULL
the	NULL
specific	NULL
JAK-STAT	NULL
signaling	NULL
events	NULL
directed	NULL
by	NULL
the	NULL
IL-7	NULL
receptor	NULL
complex	NULL
are	NULL
independent	NULL
of	NULL
the	NULL
tyrosine	NULL
residues	NULL
of	NULL
the	NULL
y	NULL
,	NULL
subunit	NULL
.	NULL

Only	NULL
the	NULL
membrane-proximal	NULL
portion	NULL
of	NULL
the	NULL
y	NULL
,	NULL
subunit	NULL
is	NULL
necessary	NULL
for	NULL
growth	NULL
signaling	NULL
by	NULL
the	NULL
IL-7R	NULL
.	NULL

Growth	NULL
signaling	NULL
mediated	NULL
by	NULL
the	NULL
chimeric	NULL
EPO7/EPOy	NULL
heterodimer	NULL
was	NULL
evaluated	NULL
in	NULL
32D/IRS-1	NULL
stable	NULL
cell	NULL
lines	NULL
.	NULL

In	NULL
PH	NULL
]	NULL
thymidine	NULL
incorporation	NULL
assays	NULL
,	NULL
EPO	NULL
stimulation	NULL
of	NULL
the	NULL
32D/IRS-1/EPO7	NULL
and	NULL
32D/IRS-1/EPOy	NULL
cell	NULL
lines	NULL
did	NULL
not	NULL
induce	NULL
detectable	NULL
pro-liferative	NULL
responses	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
A	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
32D/IRS-1/EPO7y	NULL
cells	NULL
demonstrated	NULL
a	NULL
strong	NULL
,	NULL
dose-dependent	NULL
proliferation	NULL
in	NULL
response	NULL
to	NULL
EPO	NULL
.	NULL

Additionally	NULL
,	NULL
a	NULL
transient	NULL
transfection	NULL
assay	NULL
originally	NULL
established	NULL
to	NULL
study	NULL
the	NULL
IL-2R	NULL
(	NULL
44	NULL
)	NULL
was	NULL
employed	NULL
to	NULL
evaluate	NULL
IL-7R	NULL
complex	NULL
subunit	NULL
requirements	NULL
.	NULL

In	NULL
such	NULL
experi-ments	NULL
,	NULL
expression	NULL
of	NULL
the	NULL
EPOy	NULL
expression	NULL
plasmid	NULL
in	NULL
the	NULL
32D/	NULL
IRS-1/EPOT7	NULL
cell	NULL
line	NULL
restored	NULL
EPO-induced	NULL
proliferation	NULL
signaling	NULL
,	NULL
as	NULL
measured	NULL
by	NULL
[	NULL
PH	NULL
incorporation	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
B	NULL
)	NULL
.	NULL

Similarly	NULL
,	NULL
introduction	NULL
of	NULL
the	NULL
EPO7	NULL
subunit	NULL
into	NULL
the	NULL
32D/IRS-1/EPOy	NULL
cell	NULL
line	NULL
also	NULL
restored	NULL
growth	NULL
signaling	NULL
in	NULL
response	NULL
to	NULL
EPO	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
heterodimerization	NULL
of	NULL
the	NULL
IL-7R	NULL
«	NULL
and	NULL
y	NULL
,	NULL
subunits	NULL
is	NULL
necessary	NULL
and	NULL
sufficient	NULL
for	NULL
IL-7-mediated	NULL
growth	NULL
signaling	NULL
.	NULL

Establishment	NULL
of	NULL
the	NULL
transfection	NULL
assay	NULL
in	NULL
these	NULL
cells	NULL
permitted	NULL
the	NULL
rapid	NULL
assessment	NULL
of	NULL
various	NULL
y	NULL
,	NULL
mutants	NULL
in	NULL
the	NULL
IL-7R	NULL
complex	NULL
.	NULL

The	NULL
y	NULL
,	NULL
.	NULL

mutants	NULL
included	NULL
the	NULL
previously	NULL
described	NULL
EPOyYF	NULL
lacking	NULL
all	NULL
four	NULL
cytoplasmic	NULL
tyrosine	NULL
residues	NULL
,	NULL
various	NULL
truncation	NULL
mutants	NULL
,	NULL
and	NULL
internal	NULL
deletion	NULL
mutants	NULL
lacking	NULL
specific	NULL
membrane-proximal	NULL
regions	NULL
of	NULL
the	NULL
y	NULL
,	NULL
subunit	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
C	NULL
)	NULL
.	NULL

Expression	NULL
of	NULL
these	NULL
chimeric	NULL
y	NULL
,	NULL
mutants	NULL
had	NULL
been	NULL
previously	NULL
verified	NULL
(	NULL
44	NULL
)	NULL
.	NULL

As	NULL
with	NULL
JAK-STAT	NULL
signaling	NULL
,	NULL
growth	NULL
signaling	NULL
was	NULL
intact	NULL
with	NULL
the	NULL
EPOyYF	NULL
mutant	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
D	NULL
)	NULL
.	NULL

Additionally	NULL
,	NULL
truncation	NULL
of	NULL
the	NULL
y	NULL
,	NULL
subunit	NULL
to	NULL
the	NULL
Box2	NULL
region	NULL
(	NULL
EPOYy336	NULL
)	NULL
did	NULL
not	NULL
adversely	NULL
affect	NULL
EPO-mediated	NULL
prolifera-tion	NULL
.	NULL

However	NULL
,	NULL
more	NULL
severe	NULL
truncations	NULL
of	NULL
the	NULL
chimeric	NULL
y	NULL
,	NULL
mutant	NULL
(	NULL
EPOyTM	NULL
and	NULL
EPOy318	NULL
)	NULL
resulted	NULL
in	NULL
the	NULL
abrogation	NULL
of	NULL
growth	NULL
signaling	NULL
,	NULL
demonstrating	NULL
the	NULL
importance	NULL
of	NULL
the	NULL
membrane-proximal	NULL
regions	NULL
of	NULL
y	NULL
,	NULL
in	NULL
IL-7R	NULL
function	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
D	NULL
)	NULL
.	NULL

This	NULL
finding	NULL
was	NULL
further	NULL
verified	NULL
by	NULL
internal	NULL
deletion	NULL
mutants	NULL
of	NULL
the	NULL
Box1	NULL
,	NULL
V-Box	NULL
,	NULL
and	NULL
Box2	NULL
regions	NULL
of	NULL
the	NULL
y	NULL
,	NULL
chimeric	NULL
receptor	NULL
,	NULL
each	NULL
of	NULL
which	NULL
also	NULL
abolished	NULL
proliferation	NULL
signaling	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
£	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
only	NULL
the	NULL
membrane-proximal	NULL
regions	NULL
of	NULL
the	NULL
y	NULL
,	NULL
subunit	NULL
are	NULL
necessary	NULL
and	NULL
sufficient	NULL
for	NULL
growth	NULL
signaling	NULL
mediated	NULL
by	NULL
the	NULL
IL-7Ra/y	NULL
,	NULL
heterodimer	NULL
.	NULL

The	NULL
y	NULL
,	NULL
subunit	NULL
is	NULL
functionally	NULL
replaceable	NULL
in	NULL
the	NULL
IL-7R	NULL
complex	NULL
for	NULL
signal	NULL
transduction	NULL
.	NULL

Previous	NULL
studies	NULL
of	NULL
the	NULL
IL-2R	NULL
complex	NULL
demonstrated	NULL
that	NULL
the	NULL
y	NULL
,	NULL
subunit	NULL
serves	NULL
primarily	NULL
to	NULL
activate	NULL
receptor	NULL
signaling	NULL
,	NULL
rather	NULL
than	NULL
to	NULL
determine	NULL
specific	NULL
signaling	NULL
events	NULL
(	NULL
52	NULL
)	NULL
.	NULL

Since	NULL
comparable	NULL
minimal	NULL
structural	NULL
elements	NULL
of	NULL
the	NULL
y	NULL
,	NULL
subunit	NULL
are	NULL
required	NULL
for	NULL
IL-7R	NULL
signaling	NULL
,	NULL
it	NULL
is	NULL
reasonable	NULL
to	NULL
predict	NULL
that	NULL
y	NULL
,	NULL
.	NULL

may	NULL
perform	NULL
a	NULL
similar	NULL
function	NULL
in	NULL
the	NULL
IL-7Ra	NULL
«	NULL
/y	NULL
,	NULL
heterodimer	NULL
.	NULL

To	NULL
test	NULL
this	NULL
hypothesis	NULL
,	NULL
the	NULL
y	NULL
,	NULL
subunit	NULL
was	NULL
replaced	NULL
by	NULL
a	NULL
heterologous	NULL
receptor	NULL
subunit	NULL
in	NULL
the	NULL
chimeric	NULL
receptor	NULL
system	NULL
.	NULL

Specifically	NULL
,	NULL
the	NULL
EPOy	NULL
subunit	NULL
was	NULL
substituted	NULL
by	NULL
a	NULL
truncated	NULL
EPOR	NULL
mutant	NULL
,	NULL
EPOR	NULL
(	NULL
1-321	NULL
)	NULL
,	NULL
which	NULL
retains	NULL
only	NULL
the	NULL
membrane-proximal	NULL
cytoplasmic	NULL
region	NULL
that	NULL
mediates	NULL
JAK2	NULL
association	NULL
(	NULL
53	NULL
)	NULL
.	NULL

In	NULL
PH	NULL
]	NULL
thymidine-incor-poration	NULL
assays	NULL
,	NULL
32D/IRS-1	NULL
stable	NULL
cell	NULL
lines	NULL
expressing	NULL
EPO7	NULL
or	NULL
EPOR	NULL
(	NULL
1-321	NULL
)	NULL
alone	NULL
did	NULL
not	NULL
demonstrate	NULL
a	NULL
detectable	NULL
proliferation	NULL
signal	NULL
in	NULL
response	NULL
to	NULL
EPO	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
A	NULL
)	NULL
.	NULL

However	NULL
,	NULL
EPO	NULL
induced	NULL
a	NULL
vigorous	NULL
growth	NULL
response	NULL
in	NULL
cells	NULL
that	NULL
expressed	NULL
both	NULL
receptor	NULL
subunits	NULL
[	NULL
32D/IRS-1/EPO7/EPOR	NULL
(	NULL
1-321	NULL
)	NULL
]	NULL
.	NULL

Thus	NULL
,	NULL
174	NULL
_	NULL
Lai	NULL
et	NULL
al	NULL
.	NULL

32D/IRS-1/EPOy	NULL
150000	NULL
-L-	NULL
vector	NULL
100000	NULL
--	NULL
-	NULL
EPOT7	NULL
-*-	NULL
_	NULL
EPO7TTR	NULL
50000	NULL
8	NULL
10	NULL
12	NULL
14	NULL
16	NULL
DAY	NULL
[	NULL
3H	NULL
]	NULL
Thymidine	NULL
Incorporation	NULL
(	NULL
cpm	NULL
)	NULL
Figure	NULL
5	NULL
.	NULL

The	NULL
cytoplasmic	NULL
domain	NULL
of	NULL
the	NULL
IL-7Ra	NULL
«	NULL
subunit	NULL
is	NULL
required	NULL
for	NULL
proliferation	NULL
signaling	NULL
.	NULL

Transient	NULL
transfection	NULL
assay	NULL
was	NULL
performed	NULL
in	NULL
32D/IRS-1/EPOy	NULL
cells	NULL
.	NULL

downstream	NULL
signaling	NULL
events	NULL
such	NULL
as	NULL
proliferation	NULL
were	NULL
unaffected	NULL
by	NULL
the	NULL
substitution	NULL
of	NULL
the	NULL
y	NULL
,	NULL
cytoplasmic	NULL
domain	NULL
by	NULL
the	NULL
truncated	NULL
EPOR	NULL
subunit	NULL
.	NULL

Distinct	NULL
molecular	NULL
signaling	NULL
events	NULL
were	NULL
evaluated	NULL
to	NULL
examine	NULL
other	NULL
potential	NULL
consequences	NULL
of	NULL
this	NULL
receptor	NULL
subunit	NULL
substitution	NULL
.	NULL

As	NULL
described	NULL
above	NULL
,	NULL
the	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
JAK1	NULL
and	NULL
JAK3	NULL
was	NULL
increased	NULL
upon	NULL
EPO-stimulation	NULL
of	NULL
the	NULL
32DEPOT7y	NULL
cell	NULL
line	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
B	NULL
)	NULL
.	NULL

In	NULL
the	NULL
32DEPOT7/EPOR	NULL
(	NULL
1-321	NULL
)	NULL
cell	NULL
line	NULL
,	NULL
EPO	NULL
stimulation	NULL
resulted	NULL
in	NULL
the	NULL
increased	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
JAK1	NULL
and	NULL
JAK2	NULL
,	NULL
but	NULL
not	NULL
of	NULL
JAK3	NULL
.	NULL

Furthermore	NULL
,	NULL
this	NULL
replacement	NULL
of	NULL
JAK3	NULL
by	NULL
JAK2	NULL
in	NULL
the	NULL
IL-7R	NULL
complex	NULL
did	NULL
not	NULL
alter	NULL
the	NULL
specificity	NULL
of	NULL
the	NULL
JAK-STAT	NULL
pathway	NULL
.	NULL

EMSA	NULL
of	NULL
nuclear	NULL
extracts	NULL
from	NULL
32D/IRS-1/EPOT7	NULL
and	NULL
32D/IRS-1/EPOR	NULL
(	NULL
1-321	NULL
)	NULL
cells	NULL
demonstrated	NULL
no	NULL
detectable	NULL
DNA-binding	NULL
activity	NULL
in	NULL
response	NULL
to	NULL
EPO	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
C	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
EPO	NULL
stimulated	NULL
the	NULL
induction	NULL
of	NULL
STAT-5	NULL
in	NULL
32D/IRS-1/	NULL
EPO7/EPOR	NULL
(	NULL
1-321	NULL
)	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
C	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Additionally	NULL
,	NULL
signaling	NULL
through	NULL
the	NULL
IL-7R	NULL
complex	NULL
results	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
IRS-1	NULL
(	NULL
41	NULL
)	NULL
.	NULL

Immunoblot	NULL
analysis	NULL
with	NULL
the	NULL
antiphosphotyrosine	NULL
antibody	NULL
of	NULL
anti-IRS-1	NULL
immunoprecipitates	NULL
demonstrated	NULL
no	NULL
detectable	NULL
increase	NULL
in	NULL
phosphorylation	NULL
of	NULL
IRS-1	NULL
in	NULL
EPO-stimulated	NULL
32D/IRS-1/EPO7	NULL
or	NULL
32D/IRS-1/	NULL
EPOy	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
IRS-1	NULL
demonstrated	NULL
a	NULL
marked	NULL
EPO-dependent	NULL
increase	NULL
in	NULL
tyrosine	NULL
phosphorylation	NULL
in	NULL
32D/IRS-1/EPOT7y	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
D	NULL
)	NULL
.	NULL

Similarly	NULL
,	NULL
IRS-1	NULL
was	NULL
phosphorylated	NULL
upon	NULL
EPO-induced	NULL
heterodimerization	NULL
of	NULL
the	NULL
IL-7Ra	NULL
and	NULL
truncated	NULL
EPOR	NULL
(	NULL
1-321	NULL
)	NULL
cytoplasmic	NULL
tails	NULL
.	NULL

Therefore	NULL
,	NULL
a	NULL
variety	NULL
of	NULL
specific	NULL
signaling	NULL
events	NULL
mediated	NULL
by	NULL
the	NULL
IL-7R	NULL
complex	NULL
occur	NULL
independently	NULL
of	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
y	NULL
,	NULL
subunit	NULL
.	NULL

The	NULL
y	NULL
,	NULL
subunit	NULL
therefore	NULL
appears	NULL
to	NULL
serve	NULL
primarily	NULL
to	NULL
activate	NULL
signaling	NULL
by	NULL
the	NULL
IL-7R	NULL
,	NULL
rather	NULL
than	NULL
to	NULL
specify	NULL
signaling	NULL
events	NULL
directed	NULL
by	NULL
the	NULL
receptor	NULL
complex	NULL
.	NULL

The	NULL
distal	NULL
portion	NULL
of	NULL
the	NULL
IL-7Ra	NULL
subunit	NULL
is	NULL
required	NULL
for	NULL
growth	NULL
signaling	NULL
.	NULL

Because	NULL
the	NULL
major	NULL
role	NULL
of	NULL
the	NULL
y	NULL
,	NULL
subunit	NULL
within	NULL
the	NULL
IL-7	NULL
receptor	NULL
complex	NULL
appears	NULL
to	NULL
be	NULL
during	NULL
initiation	NULL
of	NULL
receptor	NULL
signaling	NULL
,	NULL
it	NULL
was	NULL
hypothesized	NULL
that	NULL
the	NULL
IL-7Ra	NULL
subunit	NULL
itself	NULL
serves	NULL
to	NULL
direct	NULL
distinct	NULL
signaling	NULL
events	NULL
.	NULL

Specifically	NULL
,	NULL
the	NULL
IL-7Ra	NULL
subunit	NULL
contains	NULL
three	NULL
tyrosine	NULL
residues	NULL
in	NULL
the	NULL
distal	NULL
portion	NULL
of	NULL
the	NULL
cytoplasmic	NULL
tail	NULL
,	NULL
which	NULL
may	NULL
serve	NULL
as	NULL
docking	NULL
sites	NULL
for	NULL
various	NULL
signaling	NULL
molecules	NULL
.	NULL

To	NULL
evaluate	NULL
the	NULL
functional	NULL
contribution	NULL
of	NULL
IL-7Ra	NULL
«	NULL
in	NULL
the	NULL
receptor	NULL
complex	NULL
,	NULL
a	NULL
chimeric	NULL
receptor	NULL
containing	NULL
the	NULL
extracellular	NULL
portion	NULL
of	NULL
EPOR	NULL
and	NULL
a	NULL
truncated	NULL
cytoplasmic	NULL
portion	NULL
of	NULL
the	NULL
IL-7Ra	NULL
«	NULL
subunit	NULL
lacking	NULL
the	NULL
three	NULL
distal	NULL
tyrosines	NULL
(	NULL
EPOT7gq	NULL
)	NULL
was	NULL
con-structed	NULL
.	NULL

Expression	NULL
of	NULL
the	NULL
EPO7g	NULL
subunit	NULL
was	NULL
verified	NULL
by	NULL
immunoblotting	NULL
of	NULL
lysates	NULL
from	NULL
transfected	NULL
COS	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
a	NULL
transient	NULL
transfection	NULL
assay	NULL
,	NULL
expression	NULL
of	NULL
the	NULL
wild-type	NULL
EPOT7	NULL
subunit	NULL
in	NULL
32D/IRS-1/EPOy	NULL
cells	NULL
led	NULL
to	NULL
the	NULL
proliferation	NULL
of	NULL
these	NULL
cells	NULL
in	NULL
response	NULL
to	NULL
EPO	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

Strik-ingly	NULL
,	NULL
introduction	NULL
of	NULL
the	NULL
EPO7	NULL
;	NULL
rg	NULL
subunit	NULL
into	NULL
this	NULL
same	NULL
cell	NULL
line	NULL
did	NULL
not	NULL
restore	NULL
growth	NULL
signaling	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
IL-7Ra	NULL
«	NULL
subunit	NULL
and	NULL
specifically	NULL
,	NULL
its	NULL
distal	NULL
cytoplasmic	NULL
domain	NULL
,	NULL
are	NULL
critical	NULL
for	NULL
proliferation	NULL
signaling	NULL
in	NULL
the	NULL
IL-7	NULL
receptor	NULL
complex	NULL
.	NULL

Discussion	NULL
Genetic	NULL
analysis	NULL
indicates	NULL
that	NULL
human	NULL
X-SCID	NULL
results	NULL
from	NULL
mutations	NULL
in	NULL
the	NULL
y	NULL
,	NULL
subunit	NULL
(	NULL
11	NULL
,	NULL
12	NULL
)	NULL
,	NULL
a	NULL
receptor	NULL
chain	NULL
shared	NULL
by	NULL
several	NULL
cytokine	NULL
receptors	NULL
(	NULL
1-9	NULL
)	NULL
.	NULL

While	NULL
recent	NULL
observations	NULL
suggest	NULL
that	NULL
the	NULL
most	NULL
critical	NULL
functional	NULL
defects	NULL
in	NULL
X-SCID	NULL
are	NULL
manifested	NULL
in	NULL
the	NULL
IL-7R	NULL
system	NULL
(	NULL
23	NULL
,	NULL
24	NULL
,	NULL
54	NULL
,	NULL
55	NULL
)	NULL
,	NULL
the	NULL
specific	NULL
role	NULL
of	NULL
y	NULL
,	NULL
in	NULL
that	NULL
receptor	NULL
complex	NULL
remains	NULL
poorly	NULL
defined	NULL
.	NULL

The	NULL
present	NULL
studies	NULL
analyzing	NULL
the	NULL
functional	NULL
architecture	NULL
of	NULL
the	NULL
IL-7R	NULL
complex	NULL
demonstrate	NULL
the	NULL
essential	NULL
requirement	NULL
of	NULL
y	NULL
,	NULL
for	NULL
proper	NULL
IL-7R	NULL
function	NULL
.	NULL

Furthermore	NULL
,	NULL
these	NULL
studies	NULL
define	NULL
the	NULL
role	NULL
of	NULL
y	NULL
,	NULL
in	NULL
the	NULL
IL-7R	NULL
complex	NULL
,	NULL
leading	NULL
to	NULL
a	NULL
potential	NULL
molecular	NULL
mechanism	NULL
for	NULL
the	NULL
pathogenesis	NULL
of	NULL
X-SCID	NULL
.	NULL

Structure/function	NULL
analysis	NULL
using	NULL
a	NULL
chimeric	NULL
receptor	NULL
system	NULL
demonstrated	NULL
the	NULL
absolute	NULL
requirement	NULL
for	NULL
heterodimerization	NULL
of	NULL
the	NULL
IL-7Ra	NULL
and	NULL
y	NULL
,	NULL
cytoplasmic	NULL
domains	NULL
to	NULL
activate	NULL
IL-7-specific	NULL
signaling	NULL
events	NULL
.	NULL

The	NULL
EPO7/EPOy	NULL
heterodimer	NULL
activated	NULL
STAT-5A	NULL
and	NULL
-5B	NULL
in	NULL
both	NULL
HT-2	NULL
and	NULL
32D/IRS-1	NULL
stable	NULL
transfectants	NULL
.	NULL

However	NULL
,	NULL
in	NULL
the	NULL
HT-2	NULL
cellular	NULL
context	NULL
,	NULL
STAT-5	NULL
activation	NULL
alone	NULL
was	NULL
not	NULL
sufficient	NULL
to	NULL
mediate	NULL
proliferation	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
a	NULL
finding	NULL
that	NULL
is	NULL
presently	NULL
being	NULL
inves-tigated	NULL
.	NULL

In	NULL
the	NULL
32D/IRS-1	NULL
stable	NULL
cell	NULL
line	NULL
,	NULL
these	NULL
molecular	NULL
events	NULL
were	NULL
not	NULL
affected	NULL
by	NULL
mutations	NULL
in	NULL
the	NULL
y	NULL
,	NULL
subunit	NULL
that	NULL
COOH	NULL
terminally	NULL
truncated	NULL
the	NULL
cytoplasmic	NULL
domain	NULL
to	NULL
the	NULL
membrane-proximal	NULL
Box2	NULL
region	NULL
or	NULL
converted	NULL
the	NULL
four	NULL
cytoplasmic	NULL
tyrosine	NULL
residues	NULL
to	NULL
phenylalanines	NULL
.	NULL

However	NULL
,	NULL
more	NULL
severe	NULL
truncation	NULL
mutants	NULL
or	NULL
internal	NULL
deletions	NULL
of	NULL
the	NULL
membrane-proximal	NULL
region	NULL
of	NULL
y	NULL
,	NULL
that	NULL
binds	NULL
JAK3	NULL
(	NULL
7	NULL
)	NULL
abolished	NULL
proliferation	NULL
signaling	NULL
.	NULL

These	NULL
results	NULL
complement	NULL
recent	NULL
studies	NULL
in	NULL
which	NULL
a	NULL
severely	NULL
truncated	NULL
y	NULL
,	NULL
subunit	NULL
acted	NULL
in	NULL
a	NULL
domi-nant-negative	NULL
fashion	NULL
to	NULL
inhibit	NULL
IL-7-mediated	NULL
growth	NULL
signaling	NULL
(	NULL
56	NULL
)	NULL
and	NULL
demonstrate	NULL
the	NULL
critical	NULL
contribution	NULL
of	NULL
the	NULL
membrane-proximal	NULL
segment	NULL
of	NULL
y	NULL
,	NULL
to	NULL
IL-7R	NULL
function	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
a	NULL
relatively	NULL
distal	NULL
truncation	NULL
of	NULL
the	NULL
IL-7Ra	NULL
«	NULL
subunit	NULL
completely	NULL
abrogated	NULL
growth	NULL
signaling	NULL
by	NULL
the	NULL
IL-7R	NULL
complex	NULL
in	NULL
the	NULL
present	NULL
system	NULL
.	NULL

Thus	NULL
,	NULL
while	NULL
both	NULL
receptor	NULL
subunits	NULL
were	NULL
observed	NULL
to	NULL
be	NULL
essential	NULL
for	NULL
IL-7R	NULL
signaling	NULL
competence	NULL
,	NULL
the	NULL
structural	NULL
requirements	NULL
for	NULL
these	NULL
subunits	NULL
were	NULL
quite	NULL
distinct	NULL
.	NULL

Collectively	NULL
,	NULL
these	NULL
findings	NULL
demonstrate	NULL
an	NULL
asymmetric	NULL
structure/function	NULL
organization	NULL
in	NULL
the	NULL
IL-7R	NULL
complex	NULL
that	NULL
is	NULL
strikingly	NULL
similar	NULL
to	NULL
the	NULL
``	NULL
trigger-driver	NULL
``	NULL
arrangement	NULL
of	NULL
the	NULL
IL-2R	NULL
complex	NULL
(	NULL
20	NULL
)	NULL
.	NULL

In	NULL
this	NULL
configuration	NULL
,	NULL
specific	NULL
receptor	NULL
signaling	NULL
events	NULL
are	NULL
determined	NULL
by	NULL
a	NULL
distinct	NULL
profile	NULL
of	NULL
signaling	NULL
intermediates	NULL
that	NULL
physically	NULL
associate	NULL
with	NULL
a	NULL
single	NULL
``	NULL
driver	NULL
``	NULL
subunit	NULL
,	NULL
represented	NULL
by	NULL
the	NULL
IL-7Ra	NULL
«	NULL
chain	NULL
.	NULL

For	NULL
example	NULL
,	NULL
these	NULL
interactions	NULL
may	NULL
be	NULL
mediated	NULL
by	NULL
conserved	NULL
SH2	NULL
or	NULL
PTB	NULL
domains	NULL
within	NULL
signaling	NULL
molecules	NULL
that	NULL
interact	NULL
with	NULL
phosphorylated	NULL
tyrosine	NULL
residues	NULL
embedded	NULL
within	NULL
specific	NULL
peptide	NULL
motifs	NULL
of	NULL
such	NULL
receptor	NULL
subunits	NULL
(	NULL
57	NULL
,	NULL
58	NULL
)	NULL
.	NULL

Indeed	NULL
,	NULL
in	NULL
the	NULL
IL-7Ra	NULL
chain	NULL
,	NULL
removal	NULL
of	NULL
the	NULL
three	NULL
distal	NULL
tyrosine	NULL
residues	NULL
was	NULL
sufficient	NULL
to	NULL
abolish	NULL
growth	NULL
signaling	NULL
by	NULL
IL-7R	NULL
.	NULL

This	NULL
finding	NULL
is	NULL
consistent	NULL
with	NULL
the	NULL
recent	NULL
studies	NULL
of	NULL
the	NULL
murine	NULL
IL-7Ra	NULL
subunit	NULL
,	NULL
which	NULL
demonstrated	NULL
the	NULL
importance	NULL
of	NULL
a	NULL
distal	NULL
tyrosine	NULL
residue	NULL
for	NULL
proliferation	NULL
in	NULL
B	NULL
cell	NULL
lymphopoiesis	NULL
(	NULL
59	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
IL-7Ra	NULL
subunit	NULL
functions	NULL
as	NULL
a	NULL
``	NULL
driver	NULL
``	NULL
subunit	NULL
in	NULL
determining	NULL
the	NULL
specific	NULL
signaling	NULL
events	NULL
mediated	NULL
by	NULL
the	NULL
IL-7R	NULL
complex	NULL
.	NULL

As	NULL
in	NULL
another	NULL
y.-containing	NULL
receptor	NULL
,	NULL
the	NULL
IL-2R	NULL
system	NULL
,	NULL
the	NULL
y.	NULL
subunit	NULL
transports	NULL
JAK3	NULL
into	NULL
the	NULL
IL-7R	NULL
complex	NULL
to	NULL
activate	NULL
receptor	NULL
signaling	NULL
.	NULL

The	NULL
initimate	NULL
association	NULL
of	NULL
y	NULL
,	NULL
and	NULL
JAK3	NULL
is	NULL
confirmed	NULL
by	NULL
patients	NULL
with	NULL
JAK3	NULL
mutations	NULL
who	NULL
have	NULL
immu-nodeficiencies	NULL
that	NULL
are	NULL
very	NULL
similar	NULL
to	NULL
X-SCID	NULL
(	NULL
60	NULL
)	NULL
.	NULL

Indeed	NULL
,	NULL
y.-	NULL
and	NULL
JAK3-deletion	NULL
mice	NULL
share	NULL
similar	NULL
immunodeficiency	NULL
phenotypes	NULL
(	NULL
13	NULL
,	NULL
14	NULL
,	NULL
61	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
the	NULL
nonfunctional	NULL
y	NULL
,	NULL
mutants	NULL
employed	NULL
in	NULL
the	NULL
present	NULL
studies	NULL
affected	NULL
similar	NULL
portions	NULL
of	NULL
the	NULL
y	NULL
,	NULL
subunit	NULL
as	NULL
mutations	NULL
found	NULL
in	NULL
X-SCID	NULL
patients	NULL
(	NULL
11	NULL
,	NULL
12	NULL
)	NULL
,	NULL
and	NULL
disrupted	NULL
the	NULL
membrane-proximal	NULL
region	NULL
of	NULL
y	NULL
,	NULL
reported	NULL
to	NULL
mediate	NULL
association	NULL
with	NULL
JAK3	NULL
(	NULL
7	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
requirement	NULL
for	NULL
JAK3	NULL
itself	NULL
within	NULL
this	NULL
signaling	NULL
complex	NULL
is	NULL
not	NULL
absolute	NULL
.	NULL

Functional	NULL
replacement	NULL
of	NULL
the	NULL
y	NULL
,	NULL
cytoplasmic	NULL
domain	NULL
by	NULL
EPOR	NULL
(	NULL
1-321	NULL
)	NULL
did	NULL
not	NULL
alter	NULL
downstream	NULL
signaling	NULL
events	NULL
measured	NULL
in	NULL
the	NULL
chimeric	NULL
IL-7R	NULL
system	NULL
.	NULL

Furthermore	NULL
,	NULL
signaling	NULL
via	NULL
the	NULL
EPO7/EPOR	NULL
(	NULL
1-321	NULL
)	NULL
heterodimer	NULL
depended	NULL
on	NULL
the	NULL
engagement	NULL
of	NULL
JAK1	NULL
and	NULL
JAK2	NULL
,	NULL
but	NULL
not	NULL
JAK3	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Importantly	NULL
,	NULL
this	NULL
substitution	NULL
of	NULL
JAK2	NULL
for	NULL
JAK3	NULL
in	NULL
this	NULL
complex	NULL
did	NULL
not	NULL
affect	NULL
events	NULL
such	NULL
as	NULL
cellular	NULL
proliferation	NULL
,	NULL
phosphorylation	NULL
of	NULL
IRS-1	NULL
,	NULL
or	NULL
induction	NULL
of	NULL
STAT-5A	NULL
or	NULL
-5B	NULL
.	NULL

Therefore	NULL
,	NULL
various	NULL
signaling	NULL
events	NULL
previously	NULL
thought	NULL
to	NULL
be	NULL
linked	NULL
to	NULL
JAK3	NULL
itself	NULL
may	NULL
instead	NULL
be	NULL
coupled	NULL
to	NULL
the	NULL
IL-7Ra	NULL
``	NULL
driver	NULL
``	NULL
chain	NULL
(	NULL
62	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
present	NULL
studies	NULL
support	NULL
the	NULL
model	NULL
that	NULL
y	NULL
,	NULL
and	NULL
JAK3	NULL
are	NULL
not	NULL
required	NULL
for	NULL
specific	NULL
signaling	NULL
events	NULL
,	NULL
but	NULL
act	NULL
instead	NULL
as	NULL
a	NULL
relatively	NULL
generic	NULL
``	NULL
trigger	NULL
``	NULL
for	NULL
activation	NULL
of	NULL
receptor-mediated	NULL
signal	NULL
transduction	NULL
.	NULL

Several	NULL
experimental	NULL
approaches	NULL
have	NULL
demonstrated	NULL
the	NULL
important	NULL
role	NULL
of	NULL
the	NULL
IL-7/IL-7R	NULL
system	NULL
to	NULL
early	NULL
lymphocyte	NULL
development	NULL
(	NULL
23	NULL
,	NULL
24	NULL
,	NULL
54	NULL
,	NULL
55	NULL
)	NULL
.	NULL

The	NULL
delineation	NULL
of	NULL
the	NULL
functional	NULL
role	NULL
of	NULL
the	NULL
y	NULL
,	NULL
subunit	NULL
within	NULL
the	NULL
IL-7R	NULL
complex	NULL
provides	NULL
a	NULL
possible	NULL
molecular	NULL
mechanism	NULL
for	NULL
the	NULL
pathogenesis	NULL
of	NULL
X-SCID	NULL
.	NULL

y	NULL
,	NULL
defects	NULL
that	NULL
prevent	NULL
the	NULL
transport	NULL
of	NULL
JAK3	NULL
into	NULL
the	NULL
receptor	NULL
complex	NULL
would	NULL
prevent	NULL
IL-7-mediated	NULL
signaling	NULL
and	NULL
the	NULL
subsequent	NULL
development	NULL
of	NULL
B	NULL
and	NULL
T	NULL
cells	NULL
.	NULL

Based	NULL
on	NULL
the	NULL
present	NULL
findings	NULL
,	NULL
the	NULL
critical	NULL
step	NULL
affected	NULL
by	NULL
mutations	NULL
in	NULL
the	NULL
y	NULL
,	NULL
subunits	NULL
appears	NULL
to	NULL
be	NULL
the	NULL
initiation	NULL
of	NULL
IL-7R	NULL
signal	NULL
transduction	NULL
.	NULL

Interestingly	NULL
,	NULL
unlike	NULL
y.-deficient	NULL
mice	NULL
and	NULL
X-SCID	NULL
patients	NULL
,	NULL
IL-7-	NULL
and	NULL
IL-7Ra-deletion	NULL
mice	NULL
retain	NULL
functional	NULL
natural	NULL
killer	NULL
cells	NULL
(	NULL
63	NULL
)	NULL
,	NULL
raising	NULL
the	NULL
possibility	NULL
that	NULL
an	NULL
unrecognized	NULL
cytokine	NULL
(	NULL
s	NULL
)	NULL
may	NULL
also	NULL
employ	NULL
y.-containing	NULL
receptor	NULL
com-plex	NULL
(	NULL
es	NULL
)	NULL
.	NULL

Nevertheless	NULL
,	NULL
the	NULL
developmental	NULL
defects	NULL
for	NULL
T	NULL
and	NULL
B	NULL
cells	NULL
are	NULL
at	NULL
least	NULL
as	NULL
severe	NULL
as	NULL
those	NULL
for	NULL
X-SCID	NULL
individuals	NULL
and	NULL
~y.-deficient	NULL
mice	NULL
.	NULL

Therefore	NULL
,	NULL
these	NULL
findings	NULL
suggest	NULL
that	NULL
the	NULL
earliest	NULL
signaling	NULL
events	NULL
that	NULL
would	NULL
affect	NULL
lymphocyte	NULL
development	NULL
in	NULL
X-SCID	NULL
appear	NULL
to	NULL
be	NULL
mediated	NULL
by	NULL
the	NULL
IL-7R	NULL
complex	NULL
.	NULL

While	NULL
the	NULL
y	NULL
,	NULL
subunit	NULL
is	NULL
present	NULL
in	NULL
other	NULL
receptor	NULL
complexes	NULL
,	NULL
such	NULL
as	NULL
the	NULL
IL-2R	NULL
,	NULL
-4R	NULL
,	NULL
-9R	NULL
,	NULL
and	NULL
-15R	NULL
,	NULL
these	NULL
receptors	NULL
appear	NULL
to	NULL
function	NULL
in	NULL
the	NULL
later	NULL
stages	NULL
of	NULL
lymphoid	NULL
development	NULL
and	NULL
regulation	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
early	NULL
block	NULL
of	NULL
lymphocyte	NULL
development	NULL
due	NULL
to	NULL
defects	NULL
in	NULL
IL-7R	NULL
function	NULL
would	NULL
mask	NULL
potential	NULL
functional	NULL
aberrations	NULL
due	NULL
to	NULL
the	NULL
lack	NULL
of	NULL
signaling	NULL
by	NULL
these	NULL
recep-tors	NULL
.	NULL

The	NULL
present	NULL
studies	NULL
define	NULL
the	NULL
role	NULL
of	NULL
y	NULL
,	NULL
in	NULL
the	NULL
IL-7R	NULL
complex	NULL
and	NULL
provide	NULL
a	NULL
possible	NULL
molecular	NULL
mechanism	NULL
for	NULL
the	NULL
pathogenesis	NULL
of	NULL
X-SCID	NULL
.	NULL

These	NULL
studies	NULL
also	NULL
define	NULL
further	NULL
at	NULL
y	NULL
,	NULL
.	NULL

Mutations	NULL
Result	NULL
in	NULL
IL-7	NULL
Receptor	NULL
Signaling	NULL
Defects	NULL
175	NULL
least	NULL
two	NULL
distinct	NULL
classes	NULL
of	NULL
receptors	NULL
that	NULL
employ	NULL
the	NULL
y	NULL
,	NULL
subunit	NULL
.	NULL

First	NULL
,	NULL
the	NULL
IL-7R	NULL
and	NULL
-2R	NULL
complexes	NULL
exhibit	NULL
a	NULL
strict	NULL
requirement	NULL
for	NULL
y	NULL
,	NULL
in	NULL
the	NULL
receptor	NULL
complex	NULL
.	NULL

In	NULL
these	NULL
receptor	NULL
systems	NULL
,	NULL
y	NULL
,	NULL
initiates	NULL
signaling	NULL
by	NULL
transporting	NULL
the	NULL
associated	NULL
JAK3	NULL
into	NULL
the	NULL
receptor	NULL
complex	NULL
,	NULL
while	NULL
IL-7Ra	NULL
«	NULL
and	NULL
-2Rf	NULL
function	NULL
in	NULL
their	NULL
respective	NULL
receptor	NULL
complexes	NULL
to	NULL
mediate	NULL
specific	NULL
signaling	NULL
events	NULL
.	NULL

Interestingly	NULL
,	NULL
a	NULL
similar	NULL
functional	NULL
arrangement	NULL
of	NULL
the	NULL
individual	NULL
receptor	NULL
subunits	NULL
has	NULL
recently	NULL
been	NULL
demonstrated	NULL
in	NULL
the	NULL
interferon-y	NULL
receptor	NULL
complex	NULL
(	NULL
64	NULL
)	NULL
.	NULL

In	NULL
the	NULL
second	NULL
class	NULL
of	NULL
receptors	NULL
,	NULL
represented	NULL
by	NULL
the	NULL
IL-4R	NULL
,	NULL
y	NULL
,	NULL
is	NULL
not	NULL
absolutely	NULL
essential	NULL
for	NULL
receptor	NULL
function	NULL
.	NULL

In	NULL
SCID-MA	NULL
cells	NULL
,	NULL
the	NULL
lack	NULL
of	NULL
detectable	NULL
y	NULL
,	NULL
expression	NULL
(	NULL
reference	NULL
12	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
does	NULL
not	NULL
affect	NULL
IL-4	NULL
responsiveness	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
and	NULL
reference	NULL
20	NULL
)	NULL
.	NULL

This	NULL
observation	NULL
supports	NULL
the	NULL
recent	NULL
findings	NULL
that	NULL
the	NULL
IL-4R	NULL
complex	NULL
may	NULL
exist	NULL
in	NULL
multiple	NULL
forms	NULL
(	NULL
17-21	NULL
)	NULL
.	NULL

In	NULL
certain	NULL
cell	NULL
lines	NULL
derived	NULL
from	NULL
X-SCID	NULL
patients	NULL
,	NULL
mutant	NULL
forms	NULL
of	NULL
y	NULL
,	NULL
may	NULL
act	NULL
in	NULL
a	NULL
dominant	NULL
negative	NULL
fashion	NULL
to	NULL
inhibit	NULL
the	NULL
IL-4-medi-ated	NULL
activation	NULL
of	NULL
JAK3	NULL
and	NULL
STAT-6	NULL
(	NULL
65	NULL
)	NULL
.	NULL

In	NULL
the	NULL
absence	NULL
of	NULL
y	NULL
,	NULL
,	NULL
another	NULL
receptor	NULL
subunit	NULL
,	NULL
perhaps	NULL
the	NULL
IL-13Ra	NULL
«	NULL
and/or	NULL
other	NULL
unidentified	NULL
partner	NULL
chains	NULL
,	NULL
may	NULL
perform	NULL
a	NULL
similar	NULL
role	NULL
as	NULL
that	NULL
of	NULL
the	NULL
y	NULL
,	NULL
subunit	NULL
during	NULL
initiation	NULL
of	NULL
signaling	NULL
through	NULL
the	NULL
receptor	NULL
complex	NULL
(	NULL
17-21	NULL
,	NULL
66	NULL
)	NULL
.	NULL

This	NULL
may	NULL
account	NULL
for	NULL
the	NULL
responsiveness	NULL
of	NULL
some	NULL
gggece-negative	NULL
cells	NULL
to	NULL
IL-4	NULL
.	NULL

Additionally	NULL
,	NULL
circumstantial	NULL
evidence	NULL
also	NULL
exists	NULL
for	NULL
a	NULL
homomeric	NULL
form	NULL
of	NULL
IL-4R	NULL
that	NULL
consists	NULL
of	NULL
only	NULL
the	NULL
IL-4Ra	NULL
subunit	NULL
(	NULL
reference	NULL
20	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Further	NULL
studies	NULL
are	NULL
in	NULL
progress	NULL
to	NULL
determine	NULL
the	NULL
functional	NULL
role	NULL
of	NULL
y	NULL
,	NULL
in	NULL
the	NULL
other	NULL
receptors	NULL
,	NULL
such	NULL
as	NULL
the	NULL
IL-9R	NULL
complex	NULL
,	NULL
and	NULL
to	NULL
understand	NULL
the	NULL
structure/function	NULL
arrangements	NULL
of	NULL
heterodimeric	NULL
receptor	NULL
systems	NULL
.	NULL

Acknowledgments	NULL
The	NULL
authors	NULL
appreciate	NULL
the	NULL
critical	NULL
comments	NULL
and	NULL
input	NULL
of	NULL
Dr.	NULL
W.C.	NULL
Greene	NULL
,	NULL
Dr.	NULL
S.L	NULL
.	NULL

Gaffen	NULL
,	NULL
and	NULL
K.D	NULL
.	NULL

Liu	NULL
.	NULL

We	NULL
thank	NULL
Dr.	NULL
R.	NULL
Geleziunas	NULL
for	NULL
the	NULL
PBMC	NULL
cDNA	NULL
used	NULL
as	NULL
a	NULL
template	NULL
in	NULL
constructing	NULL
EPO7	NULL
,	NULL
Dr.	NULL
L.	NULL
Hennighausen	NULL
for	NULL
the	NULL
anti-STAT-5A	NULL
and	NULL
anti-STAT-5B	NULL
antibodies	NULL
,	NULL
Dr.	NULL
S.L	NULL
.	NULL

McKnight	NULL
for	NULL
the	NULL
anti-STAT-6	NULL
antibody	NULL
,	NULL
Dr.	NULL
M.	NULL
White	NULL
for	NULL
the	NULL
anti-IRS-1	NULL
antibody	NULL
,	NULL
and	NULL
Dr.	NULL
J.	NULL
Puck	NULL
for	NULL
the	NULL
SCID-MA	NULL
cell	NULL
line	NULL
.	NULL

The	NULL
authors	NULL
acknowledge	NULL
the	NULL
excellent	NULL
assistance	NULL
of	NULL
Mr.	NULL
Michael	NULL
Ce-niceros	NULL
,	NULL
Mr.	NULL
John	NULL
Carroll	NULL
,	NULL
and	NULL
Ms.	NULL
Amy	NULL
Corder	NULL
in	NULL
the	NULL
preparation	NULL
of	NULL
this	NULL
manuscript	NULL
.	NULL

IL-2	NULL
was	NULL
a	NULL
generous	NULL
gift	NULL
of	NULL
Chiron	NULL
Corp.	NULL
,	NULL
and	NULL
EPO	NULL
was	NULL
the	NULL
generous	NULL
gift	NULL
of	NULL
Ortho	NULL
Diagnostic	NULL
Systems	NULL
,	NULL
Inc.	NULL
Support	NULL
for	NULL
this	NULL
work	NULL
was	NULL
provided	NULL
by	NULL
the	NULL
J.	NULL
David	NULL
Gladstone	NULL
Institutes	NULL
and	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
(	NULL
NIH	NULL
)	NULL
grant	NULL
GM-54351	NULL
to	NULL
M.A	NULL
.	NULL

Goldsmith	NULL
.	NULL

S.Y	NULL
.	NULL

Lai	NULL
is	NULL
in	NULL
the	NULL
NIH	NULL
Medical	NULL
Scientist	NULL
Training	NULL
Program	NULL
and	NULL
the	NULL
Biomedical	NULL
Sciences	NULL
Program	NULL
at	NULL
the	NULL
University	NULL
of	NULL
California	NULL
,	NULL
San	NULL
Francisco	NULL
.	NULL

References	NULL
1	NULL
.	NULL

Takeshita	NULL
,	NULL
T.	NULL
,	NULL
H.	NULL
Asao	NULL
,	NULL
K.	NULL
Ohtani	NULL
,	NULL
N.	NULL
Ishii	NULL
,	NULL
S.	NULL
Kumaki	NULL
,	NULL
N.	NULL
Tanaka	NULL
,	NULL
H.	NULL
Munakata	NULL
,	NULL
M.	NULL
Nakamura	NULL
,	NULL
and	NULL
K.	NULL
Sugamura	NULL
.	NULL

1992	NULL
.	NULL

Cloning	NULL
of	NULL
the	NULL
gamma	NULL
chain	NULL
of	NULL
the	NULL
human	NULL
IL-2	NULL
receptor	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

257:379-382	NULL
.	NULL

2	NULL
.	NULL

Kondo	NULL
,	NULL
M.	NULL
,	NULL
T.	NULL
Takeshita	NULL
,	NULL
N.	NULL
Ishii	NULL
,	NULL
M.	NULL
Nakamura	NULL
,	NULL
S.	NULL
Watanabe	NULL
,	NULL
K.-L.	NULL
Arai	NULL
,	NULL
and	NULL
K.	NULL
Sugamura	NULL
.	NULL

1993	NULL
.	NULL

Sharing	NULL
of	NULL
the	NULL
interleukin-2	NULL
(	NULL
IL-2	NULL
)	NULL
receptor	NULL
y	NULL
chain	NULL
between	NULL
receptors	NULL
for	NULL
IL-2	NULL
and	NULL
IL-4	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

262:1874-1877	NULL
.	NULL

3	NULL
.	NULL

Noguchi	NULL
,	NULL
M.	NULL
,	NULL
Y.	NULL
Nakamura	NULL
,	NULL
S.M	NULL
.	NULL

Russell	NULL
,	NULL
S.F	NULL
.	NULL

Ziegler	NULL
,	NULL
M.	NULL
Tsang	NULL
,	NULL
X.	NULL
Cao	NULL
,	NULL
and	NULL
W.J	NULL
.	NULL

Leonard	NULL
.	NULL

1993	NULL
.	NULL

Interleukin-2	NULL
receptor	NULL
y	NULL
chain	NULL
:	NULL
a	NULL
functional	NULL
component	NULL
of	NULL
the	NULL
interleukin-7	NULL
receptor	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

262:1877-1880	NULL
.	NULL

4	NULL
.	NULL

Russell	NULL
,	NULL
S.M	NULL
.	NULL

,	NULL
A.D.	NULL
Keegan	NULL
,	NULL
N.	NULL
Harada	NULL
,	NULL
Y.	NULL
Nakamura	NULL
,	NULL
M.	NULL
Noguchi	NULL
,	NULL
P.	NULL
Leland	NULL
,	NULL
M.C	NULL
.	NULL

Friedmann	NULL
,	NULL
A.	NULL
Miyajima	NULL
,	NULL
R.K.	NULL
Puri	NULL
,	NULL
W.E	NULL
.	NULL

Paul	NULL
,	NULL
and	NULL
W.J	NULL
.	NULL

Leonard	NULL
.	NULL

1993	NULL
.	NULL

Interleukin-2	NULL
receptor	NULL
y	NULL
chain	NULL
:	NULL
a	NULL
functional	NULL
component	NULL
of	NULL
the	NULL
interleukin-4	NULL
receptor	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

262:1880-1883	NULL
.	NULL

5	NULL
.	NULL

Giri	NULL
,	NULL
J.G	NULL
.	NULL

,	NULL
M.	NULL
Ahdich	NULL
,	NULL
J.	NULL
Eisenman	NULL
,	NULL
K.	NULL
Shanebeck	NULL
,	NULL
K.	NULL
Grabstein	NULL
,	NULL
S.	NULL
Kumaki	NULL
,	NULL
A.	NULL
Namen	NULL
,	NULL
L.S	NULL
.	NULL

Park	NULL
,	NULL
D.	NULL
Cosman	NULL
,	NULL
and	NULL
D.	NULL
Anderson	NULL
.	NULL

1994	NULL
.	NULL

Utilization	NULL
of	NULL
the	NULL
B	NULL
and	NULL
y	NULL
chains	NULL
of	NULL
the	NULL
IL-2	NULL
receptor	NULL
by	NULL
the	NULL
novel	NULL
cytokine	NULL
IL-15	NULL
.	NULL

EMBO	NULL
(	NULL
Eur	NULL
.	NULL

Mol	NULL
.	NULL

Biol	NULL
.	NULL

Organ	NULL
.	NULL
)	NULL

J	NULL
.	NULL

13:2822-2830	NULL
.	NULL

176	NULL
_-	NULL
Lai	NULL
et	NULL
al	NULL
.	NULL

6	NULL
.	NULL

Kondo	NULL
,	NULL
M.	NULL
,	NULL
T.	NULL
Takeshita	NULL
,	NULL
M.	NULL
Higuchi	NULL
,	NULL
M.	NULL
Nakamura	NULL
,	NULL
T.	NULL
Sudo	NULL
,	NULL
S.	NULL
Nishikawa	NULL
,	NULL
and	NULL
K.	NULL
Sugamura	NULL
.	NULL

1994	NULL
.	NULL

Functional	NULL
participation	NULL
of	NULL
the	NULL
IL-2	NULL
receptor	NULL
y	NULL
chain	NULL
in	NULL
IL-7	NULL
receptor	NULL
complexes	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

263:1453-1454	NULL
.	NULL

7	NULL
.	NULL

Russell	NULL
,	NULL
S.M	NULL
.	NULL

,	NULL
J	NULL
.	NULL

A.	NULL
Johnston	NULL
,	NULL
M.	NULL
Noguchi	NULL
,	NULL
M.	NULL
Kawamura	NULL
,	NULL
C.M	NULL
.	NULL

Bacon	NULL
,	NULL
M.	NULL
Friedmann	NULL
,	NULL
M.	NULL
Berg	NULL
,	NULL
D.W.	NULL
McVicar	NULL
,	NULL
B.A	NULL
.	NULL

Witthuhn	NULL
,	NULL
O.	NULL
Silvennoinen	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1994	NULL
.	NULL

Interaction	NULL
of	NULL
IL-2RB	NULL
and	NULL
yc	NULL
chains	NULL
with	NULL
Jak1	NULL
and	NULL
Jak3	NULL
:	NULL
implications	NULL
for	NULL
XSCID	NULL
and	NULL
XCID	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

266:1042-1045	NULL
.	NULL

8	NULL
.	NULL

Kimura	NULL
,	NULL
Y.	NULL
,	NULL
T.	NULL
Takeshita	NULL
,	NULL
M.	NULL
Kondo	NULL
,	NULL
N.	NULL
Ishii	NULL
,	NULL
M.	NULL
Nakamura	NULL
,	NULL
J	NULL
.	NULL

Van	NULL
Snick	NULL
,	NULL
and	NULL
K.	NULL
Sugamura	NULL
.	NULL

1995	NULL
.	NULL

Sharing	NULL
of	NULL
the	NULL
IL-2	NULL
receptor	NULL
gamma	NULL
chain	NULL
with	NULL
the	NULL
functional	NULL
IL-9	NULL
receptor	NULL
complex	NULL
.	NULL

Intl	NULL
.	NULL

Immunol	NULL
.	NULL

7:115-120	NULL
.	NULL

9	NULL
.	NULL

Ziegler	NULL
,	NULL
S.E	NULL
.	NULL

,	NULL
K.K	NULL
.	NULL

Morella	NULL
,	NULL
D.	NULL
Anderson	NULL
,	NULL
N.	NULL
Kumaki	NULL
,	NULL
W.J	NULL
.	NULL

Leonard	NULL
,	NULL
D.	NULL
Cosman	NULL
,	NULL
and	NULL
H.	NULL
Baumann	NULL
.	NULL

1995	NULL
.	NULL

Reconstitution	NULL
of	NULL
a	NULL
functional	NULL
IL-7	NULL
receptor	NULL
demonstrates	NULL
that	NULL
the	NULL
IL-2	NULL
receptor	NULL
gamma	NULL
chain	NULL
is	NULL
required	NULL
for	NULL
IL-7	NULL
signal	NULL
transduction	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

25:399-404	NULL
.	NULL

10	NULL
.	NULL

Conley	NULL
,	NULL
M.E	NULL
.	NULL

1992	NULL
.	NULL

Molecular	NULL
approaches	NULL
to	NULL
analysis	NULL
of	NULL
X-linked	NULL
immu-nodeficiencies	NULL
.	NULL

Ann	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

10:215-238	NULL
.	NULL

11	NULL
.	NULL

Noguchi	NULL
,	NULL
M.	NULL
,	NULL
H.	NULL
Yi	NULL
,	NULL
H.M.	NULL
Rosenblatt	NULL
,	NULL
A.H.	NULL
Filipovich	NULL
,	NULL
S.	NULL
Adelstein	NULL
,	NULL
W.S	NULL
.	NULL

Modi	NULL
,	NULL
O.W	NULL
.	NULL

McBride	NULL
,	NULL
and	NULL
W.J	NULL
.	NULL

Leonard	NULL
.	NULL

1993	NULL
.	NULL

Interleukin-2	NULL
receptor	NULL
y	NULL
chain	NULL
mutation	NULL
results	NULL
in	NULL
X-linked	NULL
severe	NULL
combined	NULL
immunodeficiency	NULL
in	NULL
hu-mans	NULL
.	NULL

Cell	NULL
.	NULL

73:147-157	NULL
.	NULL

12	NULL
.	NULL

Puck	NULL
,	NULL
J.M	NULL
.	NULL

,	NULL
S.M	NULL
.	NULL

Deschenes	NULL
,	NULL
J.C.	NULL
Porter	NULL
,	NULL
A.S.	NULL
Dutra	NULL
,	NULL
C.J	NULL
.	NULL

Brown	NULL
,	NULL
HF	NULL
.	NULL

Willard	NULL
,	NULL
and	NULL
P.S	NULL
.	NULL

Henthorn	NULL
.	NULL

1993	NULL
.	NULL

The	NULL
interleukin-2	NULL
receptor	NULL
y	NULL
chain	NULL
maps	NULL
to	NULL
Xq13.1	NULL
and	NULL
is	NULL
mutated	NULL
in	NULL
X-linked	NULL
severe	NULL
combined	NULL
immunodeficiency	NULL
,	NULL
SCIDX1	NULL
.	NULL

Hum	NULL
.	NULL

Mol	NULL
.	NULL

Genet	NULL
.	NULL

2:1099-1104	NULL
.	NULL

13	NULL
.	NULL

Cao	NULL
,	NULL
X.	NULL
,	NULL
E.W	NULL
.	NULL

Shores	NULL
,	NULL
J.	NULL
Hu-Li	NULL
,	NULL
M.R	NULL
.	NULL

Anver	NULL
,	NULL
B.L	NULL
.	NULL

Kelsall	NULL
,	NULL
S.M	NULL
.	NULL

Russell	NULL
,	NULL
J.	NULL
Drago	NULL
,	NULL
M.	NULL
Noguchi	NULL
,	NULL
A.	NULL
Grinberg	NULL
,	NULL
E.T	NULL
.	NULL

Bloom	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1995	NULL
.	NULL

Defective	NULL
lymphoid	NULL
development	NULL
in	NULL
mice	NULL
lacking	NULL
expression	NULL
of	NULL
the	NULL
common	NULL
cytokine	NULL
receptor	NULL
y	NULL
chain	NULL
.	NULL

Immunity	NULL
.	NULL

2:223-238	NULL
.	NULL

14	NULL
.	NULL

DiSanto	NULL
,	NULL
J.P.	NULL
,	NULL
W.	NULL
Muller	NULL
,	NULL
D.	NULL
Guy-Grand	NULL
,	NULL
A.	NULL
Fischer	NULL
,	NULL
and	NULL
K.	NULL
Rajewsky	NULL
.	NULL

1995	NULL
.	NULL

Lymphoid	NULL
development	NULL
in	NULL
mice	NULL
with	NULL
a	NULL
targeted	NULL
deletion	NULL
of	NULL
the	NULL
interleukin-2	NULL
receptor	NULL
y	NULL
chain	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

92:377-381	NULL
.	NULL

15	NULL
.	NULL

Schorle	NULL
,	NULL
H.	NULL
,	NULL
T.	NULL
Holtschke	NULL
,	NULL
T.	NULL
Hunig	NULL
,	NULL
A.	NULL
Schimpl	NULL
,	NULL
and	NULL
I.	NULL
Horak	NULL
.	NULL

1991	NULL
.	NULL

Development	NULL
and	NULL
function	NULL
of	NULL
T	NULL
cells	NULL
in	NULL
mice	NULL
rendered	NULL
interleukin-2	NULL
deficient	NULL
by	NULL
gene	NULL
targeting	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

.	NULL

352:621-624	NULL
.	NULL

16	NULL
.	NULL

Suzuki	NULL
,	NULL
H.	NULL
,	NULL
TM	NULL
.	NULL

Kundig	NULL
,	NULL
C.	NULL
Furlonger	NULL
,	NULL
A.	NULL
Wakeham	NULL
,	NULL
E.	NULL
Timms	NULL
,	NULL
T.	NULL
Matsuyama	NULL
,	NULL
R.	NULL
Schmits	NULL
,	NULL
J.J.	NULL
Simard	NULL
,	NULL
P.S	NULL
.	NULL

Ohashi	NULL
,	NULL
and	NULL
H.	NULL
Griesser	NULL
.	NULL

1995	NULL
.	NULL

Deregulated	NULL
T	NULL
cell	NULL
activation	NULL
and	NULL
autoimmunity	NULL
in	NULL
mice	NULL
lacking	NULL
interleukin-2	NULL
receptor	NULL
beta	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

268:1472-1476	NULL
.	NULL

17	NULL
.	NULL

He	NULL
,	NULL
Y.-W.	NULL
,	NULL
and	NULL
T.R	NULL
.	NULL

Malek	NULL
.	NULL

1995	NULL
.	NULL

The	NULL
IL-2	NULL
receptor	NULL
y	NULL
,	NULL
chain	NULL
does	NULL
not	NULL
function	NULL
as	NULL
a	NULL
subunit	NULL
shared	NULL
by	NULL
the	NULL
IL-4	NULL
and	NULL
IL-13	NULL
receptors	NULL
:	NULL
implication	NULL
for	NULL
the	NULL
structure	NULL
of	NULL
the	NULL
IL-4	NULL
receptor	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

155:9-12	NULL
.	NULL

18	NULL
.	NULL

Keegan	NULL
,	NULL
A.D.	NULL
,	NULL
J.A	NULL
.	NULL

Johnston	NULL
,	NULL
P.J	NULL
.	NULL

Tortolani	NULL
,	NULL
L.J	NULL
.	NULL

McReynolds	NULL
,	NULL
C.	NULL
Kin-zer	NULL
,	NULL
J.J.	NULL
O'Shea	NULL
,	NULL
and	NULL
W.E	NULL
.	NULL

Paul	NULL
.	NULL

1995	NULL
.	NULL

Similarities	NULL
and	NULL
differences	NULL
in	NULL
signal	NULL
transduction	NULL
by	NULL
IL-4	NULL
and	NULL
IL-13	NULL
:	NULL
analysis	NULL
of	NULL
Janus	NULL
kinase	NULL
activation	NULL
.	NULL

Proc	NULL
.	NULL

Nat	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

92:7681-7685	NULL
.	NULL

19	NULL
.	NULL

Lin	NULL
,	NULL
J.-X	NULL
.	NULL

,	NULL
T.-S.	NULL
Migone	NULL
,	NULL
M.	NULL
Tsang	NULL
,	NULL
M.	NULL
Friedmann	NULL
,	NULL
J.A	NULL
.	NULL

Weatherbee	NULL
,	NULL
L.	NULL
Zhou	NULL
,	NULL
A.	NULL
Yamauchi	NULL
,	NULL
E.	NULL
T.	NULL
Bloom	NULL
,	NULL
J.	NULL
Mietz	NULL
,	NULL
S.	NULL
John	NULL
,	NULL
and	NULL
W.	NULL
J.	NULL
Leonard	NULL
.	NULL

1995	NULL
.	NULL

The	NULL
role	NULL
of	NULL
shared	NULL
receptor	NULL
motifs	NULL
and	NULL
common	NULL
stat	NULL
proteins	NULL
in	NULL
the	NULL
generation	NULL
of	NULL
cytokine	NULL
pleiotropy	NULL
and	NULL
redundancy	NULL
by	NULL
IL-2	NULL
,	NULL
IL-4	NULL
,	NULL
IL-7	NULL
,	NULL
IL-13	NULL
,	NULL
and	NULL
IL-15	NULL
.	NULL

Immunity	NULL
.	NULL

2:331-339	NULL
.	NULL

20	NULL
.	NULL

Lai	NULL
,	NULL
S.Y	NULL
.	NULL

,	NULL
J.	NULL
Molden	NULL
,	NULL
K.D	NULL
.	NULL

Liu	NULL
,	NULL
J.M	NULL
.	NULL

Puck	NULL
,	NULL
M.D	NULL
.	NULL

White	NULL
,	NULL
and	NULL
M.A	NULL
.	NULL

Goldsmith	NULL
.	NULL

1996	NULL
.	NULL

Interleukin	NULL
4-specific	NULL
signal	NULL
transduction	NULL
events	NULL
are	NULL
driven	NULL
by	NULL
ho-motypic	NULL
interactions	NULL
on	NULL
the	NULL
interleukin-4	NULL
receptor	NULL
a	NULL
subunit	NULL
.	NULL

EMBO	NULL
(	NULL
Eur	NULL
.	NULL

Mol	NULL
.	NULL

Biol	NULL
.	NULL

Organ	NULL
.	NULL
)	NULL

J	NULL
.	NULL

15:4506-4514	NULL
.	NULL

21	NULL
.	NULL

Palmer-Crocker	NULL
,	NULL
R.L	NULL
.	NULL

,	NULL
C.C.W	NULL
.	NULL

Hughes	NULL
,	NULL
and	NULL
J.S	NULL
.	NULL

Pober	NULL
.	NULL

1996	NULL
.	NULL

IL-4	NULL
and	NULL
IL-13	NULL
activate	NULL
the	NULL
JAK2	NULL
tyrosine	NULL
kinase	NULL
and	NULL
Stat6	NULL
in	NULL
cultured	NULL
human	NULL
vascular	NULL
endothelial	NULL
cells	NULL
through	NULL
a	NULL
common	NULL
pathway	NULL
that	NULL
does	NULL
not	NULL
involve	NULL
the	NULL
y	NULL
,	NULL
chain	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

98:604-609	NULL
.	NULL

22	NULL
.	NULL

Renauld	NULL
,	NULL
J.C.	NULL
,	NULL
A.	NULL
Kermouni	NULL
,	NULL
A.	NULL
Vink	NULL
,	NULL
J.	NULL
Louahed	NULL
,	NULL
and	NULL
J	NULL
.	NULL

Van	NULL
Snick	NULL
.	NULL

1995	NULL
.	NULL

Interleukin-9	NULL
and	NULL
its	NULL
receptor	NULL
:	NULL
involvement	NULL
in	NULL
mast	NULL
cell	NULL
differentiation	NULL
and	NULL
T	NULL
cell	NULL
oncogenesis	NULL
.	NULL

J.	NULL
Leukocyte	NULL
Biol	NULL
.	NULL

57:353-360	NULL
.	NULL

23.	NULL
von	NULL
Freeden-Jeffry	NULL
,	NULL
U.	NULL
,	NULL
P.	NULL
Vieira	NULL
,	NULL
L.A.	NULL
Lucian	NULL
,	NULL
T.	NULL
McNeil	NULL
,	NULL
S.E	NULL
.	NULL

Burdach	NULL
,	NULL
and	NULL
R.	NULL
Murray	NULL
.	NULL

1995	NULL
.	NULL

Lymphopenia	NULL
in	NULL
interleukin	NULL
(	NULL
IL-7	NULL
)	NULL
-7	NULL
gene-deleted	NULL
mice	NULL
identifies	NULL
IL-7	NULL
as	NULL
a	NULL
nonredunant	NULL
cytokine	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

181:1519-1526	NULL
.	NULL

24	NULL
.	NULL

Peschon	NULL
,	NULL
J.J.	NULL
,	NULL
P.J	NULL
.	NULL

Morrissey	NULL
,	NULL
K.H	NULL
.	NULL

Grabstein	NULL
,	NULL
F.J.	NULL
Ramsdell	NULL
,	NULL
E.	NULL
Maras-kovsky	NULL
,	NULL
B.C	NULL
.	NULL

Gliniak	NULL
,	NULL
L.S	NULL
.	NULL

Park	NULL
,	NULL
S.F	NULL
.	NULL

Ziegler	NULL
,	NULL
D.E	NULL
.	NULL

Williams	NULL
,	NULL
C.B	NULL
.	NULL

Ware	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1994	NULL
.	NULL

Early	NULL
lymphocyte	NULL
expansion	NULL
is	NULL
severely	NULL
impaired	NULL
in	NULL
interleukin-7	NULL
recep-tor-deficient	NULL
mice	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

180:1955-1960	NULL
.	NULL

25	NULL
.	NULL

Namen	NULL
,	NULL
A.E	NULL
.	NULL

,	NULL
A.E	NULL
.	NULL

Schmierer	NULL
,	NULL
C.J	NULL
.	NULL

March	NULL
,	NULL
RW	NULL
.	NULL

Overell	NULL
,	NULL
LS	NULL
.	NULL

Park	NULL
,	NULL
D.L	NULL
.	NULL

Urdal	NULL
,	NULL
and	NULL
D.Y	NULL
.	NULL

Mochizuki	NULL
.	NULL

1988	NULL
.	NULL

B	NULL
cell	NULL
precursor	NULL
growth-promoting	NULL
ac-tivity	NULL
:	NULL
purification	NULL
and	NULL
characterization	NULL
of	NULL
a	NULL
growth	NULL
factor	NULL
active	NULL
on	NULL
lymphocyte	NULL
precursors	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

167:988-1002	NULL
.	NULL

26	NULL
.	NULL

Namen	NULL
,	NULL
A.E	NULL
.	NULL

,	NULL
S.	NULL
Lupton	NULL
,	NULL
K.	NULL
Hjerrild	NULL
,	NULL
J.	NULL
Wignall	NULL
,	NULL
D.Y	NULL
.	NULL

Mochizuki	NULL
,	NULL
A.	NULL
Schmierer	NULL
,	NULL
B.	NULL
Mosley	NULL
,	NULL
C.J	NULL
.	NULL

March	NULL
,	NULL
D.	NULL
Urdal	NULL
,	NULL
and	NULL
S.	NULL
Gillis	NULL
.	NULL

1988	NULL
.	NULL

Stimulation	NULL
of	NULL
B-cell	NULL
progenitors	NULL
by	NULL
cloned	NULL
murine	NULL
interleukin-7	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

.	NULL

333:571-573	NULL
.	NULL

27	NULL
.	NULL

Conlon	NULL
,	NULL
P.J	NULL
.	NULL

,	NULL
P.J	NULL
.	NULL

Morrissey	NULL
,	NULL
R.P	NULL
.	NULL

Nordan	NULL
,	NULL
K.H	NULL
.	NULL

Grabstein	NULL
,	NULL
K.S	NULL
.	NULL

Prick-ett	NULL
,	NULL
$	NULL
.G	NULL
.	NULL

Reed	NULL
,	NULL
R.	NULL
Goodwin	NULL
,	NULL
D.	NULL
Cosman	NULL
,	NULL
and	NULL
A.E	NULL
.	NULL

Namen	NULL
.	NULL

1989	NULL
.	NULL

Murine	NULL
thymocytes	NULL
proliferate	NULL
in	NULL
direct	NULL
response	NULL
to	NULL
interleukin-7	NULL
.	NULL

Blood	NULL
.	NULL

74:1368-1373	NULL
.	NULL

28	NULL
.	NULL

Goodwin	NULL
,	NULL
R.G	NULL
.	NULL

,	NULL
S.	NULL
Lupton	NULL
,	NULL
A.	NULL
Schmierer	NULL
,	NULL
K.J	NULL
.	NULL

Hjerrild	NULL
,	NULL
R.	NULL
Jerzy	NULL
,	NULL
W.	NULL
Clevenger	NULL
,	NULL
S.	NULL
Gillis	NULL
,	NULL
D.	NULL
Cosman	NULL
,	NULL
and	NULL
A.E	NULL
.	NULL

Namen	NULL
.	NULL

1989	NULL
.	NULL

Human	NULL
interleukin	NULL
7	NULL
:	NULL
Molecular	NULL
cloning	NULL
and	NULL
growth	NULL
factor	NULL
activity	NULL
on	NULL
human	NULL
and	NULL
murine	NULL
B-lineage	NULL
cells	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

86:302-306	NULL
.	NULL

29	NULL
.	NULL

Takeda	NULL
,	NULL
S.	NULL
,	NULL
S.	NULL
Gillis	NULL
,	NULL
and	NULL
R.	NULL
Palacios	NULL
.	NULL

1989	NULL
.	NULL

In	NULL
vitro	NULL
effects	NULL
of	NULL
recombinant	NULL
interleukin-7	NULL
on	NULL
growth	NULL
and	NULL
differentiation	NULL
of	NULL
bone	NULL
marrow	NULL
pro-B-	NULL
and	NULL
pro-T-lymphocyte	NULL
clones	NULL
and	NULL
fetal	NULL
thymocyte	NULL
clones	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

86:1634-1638	NULL
.	NULL

30	NULL
.	NULL

Okazaki	NULL
,	NULL
H.	NULL
,	NULL
M.	NULL
Ito	NULL
,	NULL
T.	NULL
Sudo	NULL
,	NULL
M.	NULL
Hattori	NULL
,	NULL
S.	NULL
Kano	NULL
,	NULL
Y.	NULL
Katsura	NULL
,	NULL
and	NULL
N.	NULL
Minato	NULL
.	NULL

1989	NULL
.	NULL

IL-7	NULL
promotes	NULL
thymocyte	NULL
proliferation	NULL
and	NULL
maintains	NULL
immuno-competent	NULL
thymocytes	NULL
bearing	NULL
alpha	NULL
beta	NULL
or	NULL
gamma	NULL
delta	NULL
T-cell	NULL
receptors	NULL
in	NULL
vitro	NULL
:	NULL
synergism	NULL
with	NULL
IL-2	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

143:2917-2922	NULL
.	NULL

31	NULL
.	NULL

Edington	NULL
,	NULL
H.	NULL
,	NULL
and	NULL
M.T	NULL
.	NULL

Lotze	NULL
.	NULL

1994	NULL
.	NULL

Interleukin-7	NULL
.	NULL

In	NULL
The	NULL
Cytokine	NULL
Handbook	NULL
.	NULL

Academic	NULL
Press	NULL
Inc.	NULL
,	NULL
Orlando	NULL
,	NULL
FL	NULL
.	NULL

169-184	NULL
.	NULL

32	NULL
.	NULL

Goodwin	NULL
,	NULL
R.G	NULL
.	NULL

,	NULL
D.	NULL
Friend	NULL
,	NULL
S.F	NULL
.	NULL

Ziegler	NULL
,	NULL
R.	NULL
Jerzy	NULL
,	NULL
B.A	NULL
.	NULL

Falk	NULL
,	NULL
S.	NULL
Gimpel	NULL
,	NULL
D.	NULL
Cosman	NULL
,	NULL
S.K	NULL
.	NULL

Dower	NULL
,	NULL
C.J	NULL
.	NULL

March	NULL
,	NULL
A.E	NULL
.	NULL

Namen	NULL
,	NULL
and	NULL
L.S	NULL
.	NULL

Park	NULL
.	NULL

1990	NULL
.	NULL

Cloning	NULL
of	NULL
the	NULL
human	NULL
and	NULL
murine	NULL
interleukin-7	NULL
receptors	NULL
:	NULL
demonstration	NULL
of	NULL
a	NULL
soluble	NULL
form	NULL
and	NULL
homology	NULL
to	NULL
a	NULL
new	NULL
receptor	NULL
superfamily	NULL
.	NULL

Cell	NULL
.	NULL

60:941-951	NULL
.	NULL

33	NULL
.	NULL

Bazan	NULL
,	NULL
J.-F.	NULL
1990	NULL
.	NULL

Structural	NULL
design	NULL
and	NULL
molecular	NULL
evolution	NULL
of	NULL
a	NULL
cytokine	NULL
receptor	NULL
superfamily	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

87:6934-6938	NULL
.	NULL

34	NULL
.	NULL

Murakami	NULL
,	NULL
M.	NULL
,	NULL
M.	NULL
Narazaki	NULL
,	NULL
M.	NULL
Hibi	NULL
,	NULL
H.	NULL
Yawata	NULL
,	NULL
K.	NULL
Yasukawa	NULL
,	NULL
M.	NULL
Hamaguchi	NULL
,	NULL
T.	NULL
Taga	NULL
,	NULL
and	NULL
T.	NULL
Kishimoto	NULL
.	NULL

1991	NULL
.	NULL

Critical	NULL
cytoplasmic	NULL
region	NULL
of	NULL
the	NULL
interleukin-6	NULL
signal	NULL
transducer	NULL
gp130	NULL
is	NULL
conserved	NULL
in	NULL
the	NULL
cytokine	NULL
receptor	NULL
fam-ily	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

88:11349-11353	NULL
.	NULL

35	NULL
.	NULL

Miyazaki	NULL
,	NULL
T.	NULL
,	NULL
A.	NULL
Kawahara	NULL
,	NULL
H.	NULL
Fujii	NULL
,	NULL
Y.	NULL
Nakagawa	NULL
,	NULL
Y.	NULL
Minami	NULL
,	NULL
Z.-J	NULL
.	NULL

Liu	NULL
,	NULL
I.	NULL
Oishi	NULL
,	NULL
O.	NULL
Silvennoinen	NULL
,	NULL
B.A	NULL
.	NULL

Witthuhn	NULL
,	NULL
J.N	NULL
.	NULL

Ihle	NULL
,	NULL
and	NULL
T.	NULL
Taniguchi	NULL
.	NULL

1994	NULL
.	NULL

Functional	NULL
activation	NULL
of	NULL
Jak1	NULL
and	NULL
Jak3	NULL
by	NULL
selective	NULL
association	NULL
with	NULL
IL-2	NULL
receptor	NULL
subunits	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

266:1045-1047	NULL
.	NULL

36	NULL
.	NULL

Wilks	NULL
,	NULL
A.F	NULL
.	NULL

,	NULL
and	NULL
A.G.	NULL
Harpur	NULL
.	NULL

1994	NULL
.	NULL

Cytokine	NULL
signal	NULL
transduction	NULL
and	NULL
the	NULL
JAK	NULL
family	NULL
of	NULL
protein	NULL
tyrosine	NULL
kinases	NULL
.	NULL

Bioessays	NULL
.	NULL

16:313-320	NULL
.	NULL

37	NULL
.	NULL

Boussiotis	NULL
,	NULL
V.A	NULL
.	NULL

,	NULL
D.L	NULL
.	NULL

Barber	NULL
,	NULL
T.	NULL
Nakarai	NULL
,	NULL
G.J	NULL
.	NULL

Freeman	NULL
,	NULL
J.G	NULL
.	NULL

Gribben	NULL
,	NULL
G.M	NULL
.	NULL

Bernstein	NULL
,	NULL
A.D.	NULL
D'Andrea	NULL
,	NULL
J.	NULL
Ritz	NULL
,	NULL
and	NULL
LM	NULL
.	NULL

Nadler	NULL
.	NULL

1994	NULL
.	NULL

Prevention	NULL
of	NULL
T	NULL
cell	NULL
anergy	NULL
by	NULL
signaling	NULL
through	NULL
the	NULL
y	NULL
,	NULL
chain	NULL
of	NULL
the	NULL
IL-2	NULL
receptor	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

266:1039-1042	NULL
.	NULL

38	NULL
.	NULL

Venkitaraman	NULL
,	NULL
A.R	NULL
.	NULL

,	NULL
and	NULL
R.J.	NULL
Cowling	NULL
.	NULL

1992	NULL
.	NULL

Interleukin-7	NULL
receptor	NULL
functions	NULL
by	NULL
recruiting	NULL
the	NULL
tyrosine	NULL
kinase	NULL
p5Qfyn	NULL
through	NULL
a	NULL
segment	NULL
of	NULL
its	NULL
cytoplasmic	NULL
tail	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

89:12083-12087	NULL
.	NULL

39	NULL
.	NULL

Seckinger	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
M.	NULL
Fougereau	NULL
.	NULL

1994	NULL
.	NULL

Activation	NULL
of	NULL
src	NULL
family	NULL
kinases	NULL
in	NULL
human	NULL
pre-B	NULL
cells	NULL
by	NULL
IL-7	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

153:97-109	NULL
.	NULL

40	NULL
.	NULL

Page	NULL
,	NULL
TH	NULL
.	NULL

,	NULL
F.	NULL
V.	NULL
Lali	NULL
,	NULL
and	NULL
B.M	NULL
.	NULL

Foxwell	NULL
.	NULL

1995	NULL
.	NULL

Interleukin-7	NULL
activates	NULL
pS6lck	NULL
and	NULL
pS59fyn	NULL
,	NULL
two	NULL
tyrosine	NULL
kinases	NULL
associated	NULL
with	NULL
the	NULL
p90	NULL
interleukin-7	NULL
receptor	NULL
in	NULL
primary	NULL
human	NULL
T	NULL
cells	NULL
.	NULL

£ur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

25:2956-2960	NULL
.	NULL

41	NULL
.	NULL

Johnston	NULL
,	NULL
J.A	NULL
.	NULL

,	NULL
LM	NULL
.	NULL

Wang	NULL
,	NULL
E.P	NULL
.	NULL

Hanson	NULL
,	NULL
X.J	NULL
.	NULL

Sun	NULL
,	NULL
MF	NULL
.	NULL

White	NULL
,	NULL
S.A.	NULL
Oakes	NULL
,	NULL
J.H	NULL
.	NULL

Pierce	NULL
,	NULL
and	NULL
J.J.	NULL
O'Shea	NULL
.	NULL

1995	NULL
.	NULL

Interleukins	NULL
2	NULL
,	NULL
4	NULL
,	NULL
7	NULL
,	NULL
and	NULL
15	NULL
stimulate	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
insulin	NULL
receptor	NULL
substrates	NULL
1	NULL
and	NULL
2	NULL
in	NULL
T	NULL
cells	NULL
:	NULL
potential	NULL
role	NULL
of	NULL
JAK	NULL
kinases	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

270:28527-28530	NULL
.	NULL

42	NULL
.	NULL

Dadi	NULL
,	NULL
HK	NULL
.	NULL

,	NULL
and	NULL
C.M	NULL
.	NULL

Roifman	NULL
.	NULL

1993	NULL
.	NULL

Activation	NULL
of	NULL
phosphatidylinositol-3	NULL
kinase	NULL
by	NULL
ligation	NULL
of	NULL
the	NULL
interleukin-7	NULL
receptor	NULL
on	NULL
human	NULL
thymocytes	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

92:1559-1563	NULL
.	NULL

43	NULL
.	NULL

Dadi	NULL
,	NULL
HK	NULL
.	NULL

,	NULL
S.	NULL
Ke	NULL
,	NULL
and	NULL
C.M	NULL
.	NULL

Roifman	NULL
.	NULL

1993	NULL
.	NULL

Interleukin-7	NULL
receptor	NULL
mediates	NULL
the	NULL
activation	NULL
of	NULL
phosphatidylinositol-3	NULL
kinase	NULL
in	NULL
human	NULL
B-cell	NULL
precursors	NULL
.	NULL

Biochem	NULL
.	NULL

Biophys	NULL
.	NULL

Res	NULL
.	NULL

Commun	NULL
.	NULL

192:459-464	NULL
.	NULL

44	NULL
.	NULL

Goldsmith	NULL
,	NULL
M.A	NULL
.	NULL

,	NULL
W.	NULL
Xu	NULL
,	NULL
M.C	NULL
.	NULL

Amaral	NULL
,	NULL
E.S	NULL
.	NULL

Kuczek	NULL
,	NULL
and	NULL
W.C.	NULL
Greene	NULL
.	NULL

1994	NULL
.	NULL

The	NULL
cytoplasmic	NULL
domain	NULL
of	NULL
the	NULL
IL-2	NULL
receptor	NULL
B	NULL
chain	NULL
contains	NULL
both	NULL
unique	NULL
and	NULL
functionally	NULL
redundant	NULL
signal	NULL
transduction	NULL
elements	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

269:14698-14704	NULL
.	NULL

45	NULL
.	NULL

Andersson	NULL
,	NULL
S.	NULL
,	NULL
D.L	NULL
.	NULL

Davis	NULL
,	NULL
H.	NULL
Dahlback	NULL
,	NULL
H.	NULL
Jornvall	NULL
,	NULL
and	NULL
D.W.	NULL
Russell	NULL
.	NULL

1989	NULL
.	NULL

Cloning	NULL
,	NULL
structure	NULL
,	NULL
and	NULL
expression	NULL
of	NULL
the	NULL
mitochondrial	NULL
cytochrome	NULL
P-450	NULL
sterol	NULL
26-hydroxylase	NULL
,	NULL
a	NULL
bile	NULL
acid	NULL
biosynthetic	NULL
enzyme	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

264:8222-8229	NULL
.	NULL

46	NULL
.	NULL

Goldsmith	NULL
,	NULL
M.A	NULL
.	NULL

,	NULL
S.Y	NULL
.	NULL

Lai	NULL
,	NULL
W.	NULL
Xu	NULL
,	NULL
M.C	NULL
.	NULL

Amaral	NULL
,	NULL
E.S	NULL
.	NULL

Kuczek	NULL
,	NULL
L.J	NULL
.	NULL

Par-ent	NULL
,	NULL
G.B	NULL
.	NULL

Mills	NULL
,	NULL
KL	NULL
.	NULL

Tarr	NULL
,	NULL
G.D.	NULL
Longmore	NULL
,	NULL
and	NULL
W.C.	NULL
Greene	NULL
.	NULL

1995	NULL
.	NULL

Growth	NULL
signal	NULL
transduction	NULL
by	NULL
the	NULL
human	NULL
IL-2	NULL
receptor	NULL
requires	NULL
cytoplasmic	NULL
tyrosines	NULL
of	NULL
the	NULL
B	NULL
chain	NULL
and	NULL
non-tyrosine	NULL
residues	NULL
of	NULL
the	NULL
y	NULL
,	NULL
chain	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

270	NULL
:	NULL
21729-21737	NULL
.	NULL

47	NULL
.	NULL

Schreiber	NULL
,	NULL
E.	NULL
,	NULL
P.	NULL
Matthias	NULL
,	NULL
M.M	NULL
.	NULL

Muller	NULL
,	NULL
and	NULL
W.	NULL
Schaffer	NULL
.	NULL

1989	NULL
.	NULL

Rapid	NULL
detection	NULL
of	NULL
octamer	NULL
binding	NULL
proteins	NULL
with	NULL
'mini-extracts	NULL
'	NULL
,	NULL
prepared	NULL
from	NULL
a	NULL
small	NULL
number	NULL
of	NULL
cells	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

17:6419	NULL
.	NULL

47a	NULL
.	NULL

Latchman	NULL
,	NULL
D.S	NULL
.	NULL

1993	NULL
.	NULL

Transcription	NULL
Factors	NULL
:	NULL
A	NULL
Practical	NULL
Approach	NULL
.	NULL

IRL	NULL
Press	NULL
at	NULL
Oxford	NULL
University	NULL
Press	NULL
,	NULL
Oxford	NULL
,	NULL
UK	NULL
.	NULL

1-26	NULL
.	NULL

48	NULL
.	NULL

Musso	NULL
,	NULL
T.	NULL
,	NULL
J.A	NULL
.	NULL

Johnston	NULL
,	NULL
D.	NULL
Linnekin	NULL
,	NULL
L.	NULL
Varesio	NULL
,	NULL
T.K	NULL
.	NULL

Rowe	NULL
,	NULL
J.J.	NULL
O'Shea	NULL
,	NULL
and	NULL
D.W.	NULL
McVicar	NULL
.	NULL

1995	NULL
.	NULL

Regulation	NULL
of	NULL
JAK3	NULL
expression	NULL
in	NULL
human	NULL
monocytes	NULL
:	NULL
phosphorylation	NULL
on	NULL
response	NULL
to	NULL
interleukins	NULL
2	NULL
,	NULL
4	NULL
,	NULL
and	NULL
7	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

181:1425-1431	NULL
.	NULL

49	NULL
.	NULL

Darnell	NULL
,	NULL
J.E	NULL
.	NULL

,	NULL
LM	NULL
.	NULL

Kerr	NULL
,	NULL
and	NULL
G.R	NULL
.	NULL

Stark	NULL
.	NULL

1994	NULL
.	NULL

Jak-STAT	NULL
pathways	NULL
and	NULL
transcriptional	NULL
activation	NULL
in	NULL
response	NULL
to	NULL
IFNs	NULL
and	NULL
other	NULL
extracellular	NULL
signaling	NULL
proteins	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

264:1415-1421	NULL
.	NULL

50	NULL
.	NULL

Wang	NULL
,	NULL
L.-M.	NULL
,	NULL
M.G	NULL
.	NULL

Myers	NULL
,	NULL
X.-J	NULL
.	NULL

Sun	NULL
,	NULL
S.A.	NULL
Aaronson	NULL
,	NULL
M.	NULL
White	NULL
,	NULL
and	NULL
J.H	NULL
.	NULL

Pierce	NULL
.	NULL

1993	NULL
.	NULL

IRS-1	NULL
:	NULL
essential	NULL
for	NULL
insulin-	NULL
and	NULL
IL-4-stimulated	NULL
mitogenesis	NULL
in	NULL
hematopoietic	NULL
cells	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

261:1591-1594	NULL
.	NULL

51	NULL
.	NULL

Gaffen	NULL
,	NULL
S.L	NULL
.	NULL

,	NULL
S.Y	NULL
.	NULL

Lai	NULL
,	NULL
M.	NULL
Ha	NULL
,	NULL
X.	NULL
Liu	NULL
,	NULL
L.	NULL
Hennighausen	NULL
,	NULL
W.C.	NULL
Greene	NULL
,	NULL
and	NULL
M.A	NULL
.	NULL

Goldsmith	NULL
.	NULL

1996	NULL
.	NULL

Distinct	NULL
tyrosine	NULL
residues	NULL
within	NULL
the	NULL
IL-2	NULL
receptor	NULL
B	NULL
chain	NULL
drive	NULL
signal	NULL
transduction	NULL
specificity	NULL
,	NULL
redundancy	NULL
and	NULL
diversity	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

271:21381-21390	NULL
.	NULL

52	NULL
.	NULL

Lai	NULL
,	NULL
S.Y	NULL
.	NULL

,	NULL
W.	NULL
Xu	NULL
,	NULL
S.L	NULL
.	NULL

Gaffen	NULL
,	NULL
G.D.	NULL
Longmore	NULL
,	NULL
W.C.	NULL
Greene	NULL
,	NULL
and	NULL
M.A	NULL
.	NULL

Goldsmith	NULL
.	NULL

1996	NULL
.	NULL

The	NULL
molecular	NULL
role	NULL
of	NULL
the	NULL
common	NULL
y	NULL
,	NULL
subunit	NULL
in	NULL
signal	NULL
transduction	NULL
reveals	NULL
functional	NULL
asymmetry	NULL
within	NULL
multimeric	NULL
cytokine	NULL
receptor	NULL
complexes	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

93:231-235	NULL
.	NULL

53	NULL
.	NULL

Witthuhn	NULL
,	NULL
B.A	NULL
.	NULL

,	NULL
FW	NULL
.	NULL

Quelle	NULL
,	NULL
O.	NULL
Silvennoinen	NULL
,	NULL
T.	NULL
Yi	NULL
,	NULL
B.	NULL
Tang	NULL
,	NULL
O.	NULL
Mi-ura	NULL
,	NULL
and	NULL
J.N	NULL
.	NULL

Ihle	NULL
.	NULL

1993	NULL
.	NULL

JAK2	NULL
associates	NULL
with	NULL
the	NULL
erythropoietin	NULL
receptor	NULL
and	NULL
is	NULL
tyrosine	NULL
phosphorated	NULL
and	NULL
activated	NULL
following	NULL
stimulation	NULL
with	NULL
erythropoietin	NULL
.	NULL

Cell	NULL
.	NULL

74:227-236	NULL
.	NULL

54	NULL
.	NULL

Grabstein	NULL
,	NULL
KH	NULL
.	NULL

,	NULL
T.J.	NULL
Waldschmidt	NULL
,	NULL
F.D	NULL
.	NULL

Finkelman	NULL
,	NULL
B.W	NULL
.	NULL

Hess	NULL
,	NULL
A.R	NULL
.	NULL

Alpert	NULL
,	NULL
N.E	NULL
.	NULL

Boiani	NULL
,	NULL
A.E	NULL
.	NULL

Namen	NULL
,	NULL
and	NULL
P.J	NULL
.	NULL

Morrissey	NULL
.	NULL

1993	NULL
.	NULL

Inhibition	NULL
of	NULL
murine	NULL
B	NULL
and	NULL
T	NULL
lymphopoiesis	NULL
in	NULL
vivo	NULL
by	NULL
an	NULL
anti-interleukin	NULL
7	NULL
monoclonal	NULL
antibody	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

178:257-264	NULL
.	NULL

55	NULL
.	NULL

Sudo	NULL
,	NULL
T.	NULL
,	NULL
S.	NULL
Nishikawa	NULL
,	NULL
N.	NULL
Ohno	NULL
,	NULL
N.	NULL
Akiyama	NULL
,	NULL
M.	NULL
Tamakoshi	NULL
,	NULL
H.	NULL
Yoshida	NULL
,	NULL
and	NULL
S.-I	NULL
.	NULL

Nishikawa	NULL
.	NULL

1993	NULL
.	NULL

Expression	NULL
and	NULL
function	NULL
of	NULL
the	NULL
interleukin	NULL
7	NULL
receptor	NULL
in	NULL
murine	NULL
lymphocytes	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

90:9125-9129	NULL
.	NULL

56	NULL
.	NULL

Kawahara	NULL
,	NULL
A.	NULL
,	NULL
Y.	NULL
Minami	NULL
,	NULL
and	NULL
T.	NULL
Taniguchi	NULL
.	NULL

1994	NULL
.	NULL

Evidence	NULL
for	NULL
a	NULL
critical	NULL
role	NULL
for	NULL
the	NULL
cytoplasmic	NULL
region	NULL
of	NULL
the	NULL
interleukin	NULL
2	NULL
(	NULL
IL-2	NULL
)	NULL
receptor	NULL
gamma	NULL
chain	NULL
in	NULL
IL-2	NULL
,	NULL
IL-4	NULL
,	NULL
and	NULL
IL-7	NULL
signaling	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14:5433-5440	NULL
.	NULL

57	NULL
.	NULL

Songyang	NULL
,	NULL
Z.	NULL
,	NULL
S.E	NULL
.	NULL

Shoelson	NULL
,	NULL
M.	NULL
Chaudhuri	NULL
,	NULL
G.	NULL
Gish	NULL
,	NULL
T.	NULL
Pawson	NULL
,	NULL
W.G	NULL
.	NULL

Haser	NULL
,	NULL
F.	NULL
King	NULL
,	NULL
T.	NULL
Roberts	NULL
,	NULL
S.	NULL
Ratnofsky	NULL
,	NULL
and	NULL
R.J.	NULL
Lechleider	NULL
.	NULL

1993	NULL
.	NULL

SH2	NULL
domains	NULL
recognize	NULL
specific	NULL
phosphopeptide	NULL
sequences	NULL
.	NULL

Cell	NULL
.	NULL

72:767-778	NULL
.	NULL

58	NULL
.	NULL

Kavanaugh	NULL
,	NULL
W.M	NULL
.	NULL

,	NULL
and	NULL
L.T	NULL
.	NULL

Williams	NULL
.	NULL

1994	NULL
.	NULL

An	NULL
alternative	NULL
to	NULL
SH2	NULL
domains	NULL
for	NULL
binding	NULL
tyrosine-phosphorylated	NULL
proteins	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

266	NULL
:	NULL
1862-1865	NULL
.	NULL

59	NULL
.	NULL

Corcoran	NULL
,	NULL
A.E	NULL
.	NULL

,	NULL
FM	NULL
.	NULL

Smart	NULL
,	NULL
R.J.	NULL
Cowling	NULL
,	NULL
T.	NULL
Crompton	NULL
,	NULL
M.J.	NULL
Owen	NULL
,	NULL
and	NULL
A.R	NULL
.	NULL

Venkitaraman	NULL
.	NULL

1996	NULL
.	NULL

The	NULL
interleukin	NULL
7	NULL
receptor	NULL
«	NULL
chain	NULL
transmits	NULL
distinct	NULL
signals	NULL
for	NULL
proliferation	NULL
and	NULL
differentiation	NULL
during	NULL
B	NULL
lymphopoiesis	NULL
.	NULL

EMBO	NULL
(	NULL
Eur	NULL
.	NULL

Mol	NULL
.	NULL

Biol	NULL
.	NULL

Organ	NULL
.	NULL
)	NULL

J	NULL
.	NULL

15:1924-1932	NULL
.	NULL

60	NULL
.	NULL

Russell	NULL
,	NULL
S.M	NULL
.	NULL

,	NULL
N.	NULL
Tayebi	NULL
,	NULL
H.	NULL
Nakajima	NULL
,	NULL
M.C	NULL
.	NULL

Riedy	NULL
,	NULL
J.L	NULL
.	NULL

Roberts	NULL
,	NULL
M.J.	NULL
Aman	NULL
,	NULL
T.S	NULL
.	NULL

Migone	NULL
,	NULL
M.	NULL
Noguchi	NULL
,	NULL
M.L	NULL
.	NULL

Markert	NULL
,	NULL
and	NULL
R.H.	NULL
Buckley	NULL
.	NULL

1995	NULL
.	NULL

Mutation	NULL
of	NULL
Jak3	NULL
in	NULL
a	NULL
patient	NULL
with	NULL
SCID	NULL
:	NULL
essential	NULL
role	NULL
of	NULL
Jak3	NULL
in	NULL
lymphoid	NULL
development	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

270:797-800	NULL
.	NULL

61	NULL
.	NULL

Nosaka	NULL
,	NULL
T.	NULL
,	NULL
J.M	NULL
.	NULL

van	NULL
Deursen	NULL
,	NULL
R.A.	NULL
Tripp	NULL
,	NULL
W.E	NULL
.	NULL

Theirfelder	NULL
,	NULL
B.A	NULL
.	NULL

Witthuhn	NULL
,	NULL
A.P	NULL
.	NULL

McMickle	NULL
,	NULL
P.C	NULL
.	NULL

Doherty	NULL
,	NULL
G.C	NULL
.	NULL

Grosveld	NULL
,	NULL
and	NULL
J.N	NULL
.	NULL

Ihle	NULL
.	NULL

1995	NULL
.	NULL

Defective	NULL
lymphoid	NULL
development	NULL
in	NULL
mice	NULL
lacking	NULL
Jak3	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

270:800-802	NULL
.	NULL

62	NULL
.	NULL

Sharfe	NULL
,	NULL
N.	NULL
,	NULL
H.	NULL
Dadi	NULL
,	NULL
and	NULL
C.M	NULL
.	NULL

Roifman	NULL
.	NULL

1995	NULL
.	NULL

JAK3	NULL
protein	NULL
tyrosine	NULL
kinase	NULL
mediates	NULL
interleukin	NULL
7-induced	NULL
activation	NULL
of	NULL
phosphatidylinositol-3	NULL
'	NULL
ki-nase	NULL
.	NULL

Blood	NULL
.	NULL

86:2077-2085	NULL
.	NULL

63	NULL
.	NULL

Maki	NULL
,	NULL
K.	NULL
,	NULL
S.	NULL
Sunaga	NULL
,	NULL
Y.	NULL
Komagata	NULL
,	NULL
Y.	NULL
Kodaira	NULL
,	NULL
A.	NULL
Mabuchi	NULL
,	NULL
H.	NULL
Kara-suyama	NULL
,	NULL
K.	NULL
Yokomuro	NULL
,	NULL
J.-L.	NULL
Miyazaki	NULL
,	NULL
and	NULL
K.	NULL
Ikuta	NULL
.	NULL

1996	NULL
.	NULL

Interleukin	NULL
7	NULL
recep-tor-deficient	NULL
mice	NULL
lack	NULL
48	NULL
T	NULL
cells	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

93:7172-7177	NULL
.	NULL

64	NULL
.	NULL

Bach	NULL
,	NULL
E.A	NULL
.	NULL

,	NULL
J.W	NULL
.	NULL

Tanner	NULL
,	NULL
S.	NULL
Marsters	NULL
,	NULL
A.	NULL
Ashkenazi	NULL
,	NULL
M.	NULL
Aguet	NULL
,	NULL
A.S.	NULL
Shaw	NULL
,	NULL
and	NULL
R.D	NULL
.	NULL

Schreiber	NULL
.	NULL

1996	NULL
.	NULL

Ligand-induced	NULL
assembly	NULL
and	NULL
activation	NULL
of	NULL
the	NULL
gamma	NULL
interferon	NULL
receptor	NULL
in	NULL
intact	NULL
cells	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

16:3214-3221	NULL
.	NULL

65	NULL
.	NULL

Izuhara	NULL
,	NULL
K.	NULL
,	NULL
T.	NULL
Heike	NULL
,	NULL
T.	NULL
Otsuka	NULL
,	NULL
K.	NULL
Yamaoka	NULL
,	NULL
M.	NULL
Mayumi	NULL
,	NULL
T.	NULL
Ima-mura	NULL
,	NULL
Y.	NULL
Niho	NULL
,	NULL
and	NULL
N.	NULL
Harada	NULL
.	NULL

1996	NULL
.	NULL

Signal	NULL
transduction	NULL
pathway	NULL
of	NULL
interleukin-4	NULL
and	NULL
interleukin-13	NULL
in	NULL
human	NULL
B	NULL
cells	NULL
derived	NULL
from	NULL
X-linked	NULL
severe	NULL
combined	NULL
immunodeficiency	NULL
patients	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

271:619-622	NULL
.	NULL

66	NULL
.	NULL

Hilton	NULL
,	NULL
D.J	NULL
.	NULL

,	NULL
J.-G.	NULL
Zhang	NULL
,	NULL
D.	NULL
Metcalf	NULL
,	NULL
W.S	NULL
.	NULL

Alexander	NULL
,	NULL
N.A	NULL
.	NULL

Nicola	NULL
,	NULL
and	NULL
T.A	NULL
.	NULL

Willson	NULL
.	NULL

1996	NULL
.	NULL

Cloning	NULL
and	NULL
characterization	NULL
of	NULL
a	NULL
binding	NULL
subunit	NULL
of	NULL
the	NULL
IL-13	NULL
receptor	NULL
that	NULL
is	NULL
also	NULL
a	NULL
component	NULL
of	NULL
the	NULL
IL-4	NULL
receptor	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

93:497-501.	NULL
y	NULL
,	NULL
.	NULL

Mutations	NULL
Result	NULL
in	NULL
IL-7	NULL
Receptor	NULL
Signaling	NULL
Defects	NULL
177	NULL

